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ABBREVIATIONS AND ACRONYMS 
 
5-FU 5-fluorouracil 
ACT Adenylate cyclase toxin 
AMP Adenosine 5'-monophosphate 
aP Acellular pertussis 
B. Bordetella 
Bp Bordetella pertussis 
cAMP cyclic adenosine 5'-monophosphate 
CHASE Cyclase/histidine kinases-associated sensing extracellular 
DNT Dermonecrotic toxin 
FHA   Filamentous haemagglutinin 
FhaC Filamentous haemagglutinin transporter protein  
FIM    Fimbriae 
HAP 6-N-hydroxylaminopurine 
HK Histidine kinase 
Hpt Histidine phosphotransferase 
Kd    Dissociation constant 
LDC Lysine decarboxylase 
LOG    LONELY GUY 
LOS Lipooligosaccharide 
M. Mycobacterium 
MALS Multi-angle light scattering 
MCD Mature C terminus distal 
NO Nitric oxide 
NOS Reactive nitrogen species 
P. Pseudomonas 
pHBA para-hydroxybenzaldehyde 
PLP Pyridoxal 5’-phosphate 
PRN Pertactin 
PT Pertussis toxin 
Rec Receiver 





RMS Root Mean Squared 
ROS Reactive oxygen species 
SEC Size-exclusion chromatographic 
SPR Surface Plasmon resonance 
StIR Stimulated Innate Resistance  
TCT Tracheal cytotoxin 
VFT Venus flytrap 















1.1  PERTUSSIS DISEASE 
 
Pertussis is a highly contagious infection of the human respiratory tract. The disease is 
commonly known as “whooping cough”, because of the characteristic inspiratory sound 
that infected people emit after cough fits. In fact, the violent and uncontrollable cough 
that distinguishes this disease often makes hard to breathe, leading ill people to deep 
breaths, which ring out as a “whooping” sound. Pertussis disease is a significant cause 
of morbidity and mortality in infants worldwide and despite high vaccination coverage, 
it continues to be a public health concern (World Health Organization 2015). 
The causative agent of whooping cough is the human pathogen Bordetella (B.) pertussis 
(Bp), a Gram-negative bacterium isolated and described for the first time by Jules 
Bordet and Octave Gengou in 1906 (Lynfield and Schaffner 2014, Kuchar, 
Karlikowska-Skwarnik et al. 2016). Pertussis disease is endemic in all countries and 
affects people of all ages, but it could be particularly intense with a fatal clinical course 
for young infants, especially of prevaccination age (Paddock, Sanden et al. 2008). 
 
1.1.1.  INFECTION AND TRANSMISSION 
 
The site of the infection is the respiratory tract (Mallory and Hornor 1912). Indeed 
Pertussis colonization begins with the adherence of B. pertussis solely to the tufts of 
ciliated epithelial cells of the upper respiratory tract: nasopharynx and trachea 
(Tuomanen and Hendley 1983) (Fig. 1). Following this attachment B. pertussis starts to 
exert its virulence producing several factors such as adhesins, immune-modulators and 
toxins which damage the cilia and cause airways to swell. The combined action of all 
these virulence factors prevents rapid clearance of the bacteria and allows them to 
replicate and to disseminate to the lower areas of the respiratory tract (de Gouw, 
Diavatopoulos et al. 2011, Zlamy 2016). 
Bordetella pertussis is transmitted from infected to susceptible individuals via 
aerosolized respiratory droplets released through coughing and sneezing (Warfel, Beren 
et al. 2012, Trainor, Nicholson et al. 2015). Whooping cough is highly contagious at the 
first stages of the disease and could be transmitted for three weeks or more without 
therapeutic intervention. In particular, vaccinated adults and adolescent, who do not 
manifest infection symptoms but host the pathogen, represent the major source of 
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transmission of bacteria to unvaccinated young infants (World Health Organization 
2015). It has been demonstrated that acellular pertussis (aP) vaccines protect against the 
developments of pertussis symptoms but not against colonization and transmission 













Figure 1. Bordetella pertussis colonization. Image at SEM of Bordetella Pertussis while adheres 
exclusively to cilia of epithelial cells in the upper respiratory tract during infection. From 
https://slideplayer.com/slide/4651572/ 
 
1.1.2  CLINICAL COURSE 
 
Pertussis clinical course may vary depending on various factors: age, presence of 
transplacentally acquired antibodies and previous infection or vaccination (McGregor, 
Ogle et al. 1986, Elliott, McIntyre et al. 2004, Kowalzik, Barbosa et al. 2007). Classical 
pertussis, seen mainly in unimmunized children, has an average of incubation period of 
7 to 10 days and it could last from 6 to 12 weeks. The illness is characterized by three 
stages: catarrhal, paroxysmal and convalescent phase. The catarrhal phase lasts from 
1 to 2 weeks and presents symptoms similar to those of many upper respiratory 
infections, like nasal congestion, lacrimation, rhinorrhea, tolerant cough and in few 
cases fever. In fact, it is not immediate to diagnose whooping cough at this stage. When 
the cough gets worse; pertussis progresses to the paroxysmal phase. Characteristic of 
this stage is the paroxysm episodes that increase in incidence and severity. They are 
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repetitive series of forceful coughs during a single expiration, followed by forced 
inspiration that produces the distinctive whoop. The post-tussive vomiting is usually a 
consequence of the paroxysms (Melvin, Scheller et al. 2014). The paroxysmal stage 
may last from 2 to 6 weeks and represents a very critical phase for infected infants less 
than 6 months. Unfortunately they do not have the strength to have a whoop and 
therefore, fall into a state of apnea resulting in bradycardia, cyanosis and 
unresponsiveness (Christie and Baltimore 1989). Only in the last phase, the 
convalescent stage, the adaptive immunity begins to execute the bacterial clearance. 
However the cessation of symptoms, paroxysms, whooping and vomiting, occurs 
gradually in a period of time ranging from 1 to 12 weeks (Melvin, Scheller et al. 2014, 
Nieves and Heininger 2016). 
In immunized or partially immune children, adolescents and adults, the clinical 
manifestations are much milder and could include coryza and cough, but without whoop 
(Nieves and Heininger 2016). In infants, less than a year old, the clinical course could 
evolve in a much more severe scenario. The bacteria can disseminate in lungs and 
induce bronchiolitis necrosis, intra-alveolar hemorrhage and fibrinous edema (Paddock, 
Sanden et al. 2008). In severe cases an excessive lymphocytosis could trigger a 
pulmonary hypertension, respiratory failure and death (Paddock, Sanden et al. 2008). 
 
1.2  BORDETELLA PERTUSSIS 
 
B. pertussis, belonging to the genus Bordetella, is an encapsulated Gram-negative, 
human-specific aerobic coccobacillus equipped with fimbriae. It is non-motile and non-
sporulating with a size approximately of 0.5 x 1 µm. 
The survival of the B. pertussis in the host depends on its ability to produce virulence 
factors able to reshape the immune system to its advantage (Higgs, Higgins et al. 2012). 
The main virulence factors are: pertussis toxin (PT), adenylate cyclase toxin (ACT), 
tracheal cytotoxin (TCT), lipooligosaccharide (LOS), filamentous haemagglutinin 
(FHA), pertactin (PRN) and type 2 and 3 fimbriae (FIM). Pertussis pathogenesis is not 
yet entirely understood, but it is demonstrated that FHA, PRN and FIM promote the 
attachment to the epithelial cells, whilst, PT, TCT and ACT contribute to elude host 
immunity and to harm the epithelium (Higgs, Higgins et al. 2012). The expression of all 
these and other factors is under the control of BvgAS locus, which encodes a two-
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component regulatory system (Weiss, Hewlett et al. 1983). This system, named BvgAS, 
perceives environmental changes and activates the expression of hundreds of genes 
(Cummings, Bootsma et al. 2006, Nicholson 2007). 
 
1.2.1  THE TWO-COMPONENT REGULATORY SYSTEM BvgAS 
 
BvgS is a 135-kDa sensor kinase composed of several domains. At N-terminal there are 
two periplasmic venus flytrap (VFT) domains followed by a transmembrane region, a 
cytoplasmic PAS domain, a histidine kinase (HK) domain, a receiver domain (Rec) and 
a last histidine phosphotransferase (Hpt) domain. BvgA is a 23-kDa response regulator 
protein containing a Rec domain at amino terminus and a DNA-binding helix-turn-helix 
domain at carboxyl terminus (Decker, James et al. 2012). Specific chemical stimuli, not 
yet identified, activate BvgS which uses ATP to phosphorylate a histidine residue in the 
HK domain, triggering the enzymatic cascade (Uhl and Miller 1994). The phosphoryl 
group is relocated from domain to domain until BvgA Rec domain. Following this 
phosphorylation BvgA dimerizes and binds to specific DNA sequences to positively or 
negatively regulate transcription (Boucher, Murakami et al. 1997, Boucher, Maris et al. 
2003). The genes regulated by BvgAS belong to four classes and their transcriptional 
regulation corresponds to three phenotypic phases: Bvg+, Bvgi and Bvg- (Fig.1). Bvg+ 
occurs when BvgAS is fully active. Class 1 genes (like toxins PT and ACT) and class 2 
genes (like FHA and FIM), known also as virulence-activated genes (vag-genes), are 
maximally expressed in this phase. Phosphorylated BvgA activates further the repressor 
protein BvgR that represses the expression of virulence-repressed genes (vrg-genes) or 
class 4 genes. Bvg+ phase is necessary and sufficient to cause infection in vivo (Cotter 
and Miller 1994). Bvgi, intermediate phase, occurs when BvgAS is partly active and the 
class 2 and class 3 genes are maximally expressed. Until now only bipA that encodes for 
an outer membrane protein, has been characterized as class3 genes. It is supposed that 
Bvgi phenotype may be involved in the transmission of the bacteria. Bvg- phase, 
instead, occurs when BvgAS is inactive and it is constituted by the highest expression of 
class 4 genes. The inactivation of BvgAS results under nutrient-limiting condition, 
therefore Bvg- phase may be essential for bacteria survival in the external environment 













Figure 2. Schematic representation of the effects of BvgAS activation on the various classes of genes 
in the three phenotypic phases. The Bvg- phase is characterized by maximal expression of class 4 genes 
and occurs when BvgAS is inactive. When instead the BvgAS is partially active, the Bvgi phase begins 
with the highest expression of class 2 and class 3 genes. With the fully activation of the two-component 
regulatory system, Bvg+ phase starts and BvgAS induces the maxima expression of class 1 and class 2 
genes. Adapted from (Melvin, Scheller et al. 2014). 
 
1.2.2  VIRULENCE FACTORS 
 
B. pertussis pathogenesis is the result of the action of several virulence factors that 
interact with host cells and coordinately alter their function. The most known B. 
pertussis virulence factors expressed during the virulent Bvg+ phase are proteins that 
can be classified as adhesins and toxins. The first category encloses surface proteins 
mainly involved in the adhesion of the bacteria starting the colonization of upper 
respiratory tract. The second one includes released proteins primarily implicated in 
impairing the epithelium and in evading host immunity. Filamentous haemagglutinin, 
pertactin and the fimbrie are the leading adhesins. FHA represents the dominant adhesin 
and is synthesized as pre-pro-protein of ~370 kDa (FhaB) to be then processed by 
peptidases to the mature form of ~250 kDa. During this process it is translocated 
through cytoplasmic membrane by Sec translocation system and across the outer 
membrane by filamentous haemagglutinin transporter protein (FhaC) (Mazar and Cotter 
2007). Mature FHA has a rod shape with its functionally essential C terminus (MCD) 
distal to the surface (Mazar and Cotter 2006). It was reported that FHA could act as an 
immune suppressor in the first steps of colonization (Inatsuka, Julio et al. 2005, 
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Villarino Romero, Osicka et al. 2014). PRN is a protein of 69 kDa and belongs to the 
classical autotransporter family of outer membrane proteins (Henderson, Navarro-
Garcia et al. 2004). In vivo PRN contributes to the adherence of the B. pertussis to 
epithe1ium (Edwards, Groathouse et al. 2005). It was also demonstrated its involvement 
in the resistance to neutrophil-mediated clearance (Inatsuka, Xu et al. 2010). The 
Fimbriae are filamentous appendages on the cell surface also known as type I pili. They 
are at the basis of Bordetella serotyping and the major serological types are FIM2 and 
FIM3. As for FHA, FIM favors the bacterial adherence to ciliated respiratory epithelium 
(Guevara, Zhang et al. 2016) and acts as suppressor of airways inflammation 
(Vandebriel, Hellwig et al. 2003). Regarding the second category, the most relevant 
members are pertussis toxin, adenylate cyclase toxin and dermonecrotic toxin (DNT). 
PT is a 105 kDa ADP-ribosylating AB5-type toxin (Stein, Boodhoo et al. 1994) 
composed of A catalytic subunit and five B membrane-binding or transport subunits, 
which compose the B pentamer. The complex is assembled in the periplasm and is 
released in the extracellular space by type IV secretion system (Kotob, Hausman et al. 
1995). PT enters in the host cells through a receptor-mediated endocytosis following a 
backward transport route up to endoplasmic reticulum from which the subunit A exits 
(el Baya, Bruckener et al. 1999). Once in the cytoplasm, the A subunit catalyzes the 
ADP-ribosylation of a cysteine residue of heterotrimeric G proteins α-subunits blocking 
the activities of enzymes regulated by G proteins. In particular it prevents G proteins to 
inhibit the adenylate cyclase activity with the consequent increase of cyclic AMP 
(cAMP). Overall the ADP- ribosylation induces a primary suppression of inflammatory 
cytokine production and an inhibition of recruiting immune cells (Graf, Codina et al. 
1992, Locht, Coutte et al. 2011). ACT belongs to RTX (repeats in toxin) toxin family 
and is secreted by type I secretion system (Glaser, Danchin et al. 1988, Carbonetti 
2010). It consists of C-terminal domain, which contains the RTX repeats and of N-
terminal domain, which possesses calmodulin-dependent adenylate cyclase activity. 
ACT through its C-terminal binds with high affinity to complement receptor 3 situated 
on neutrophils, macrophages and dendritic cells surfaces. Upon binding the RTX forms 
a cation-selective pore in plasma membrane inducing variation in ion permeability and 
the calmodulin-dependent adenylate cyclase domain moves inside the host cells 
catalyzing the conversion of ATP in cyclic AMP (Glaser, Elmaoglou-Lazaridou et al. 
1989, Ladant, Michelson et al. 1989, Sakamoto, Bellalou et al. 1992, Guermonprez, 
Khelef et al. 2001, El-Azami-El-Idrissi, Bauche et al. 2003). Increased level of cAMP 
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inhibits phagocytosis and oxidative burst in neutrophils (Confer and Eaton 1982) and 
prevents the complement-dependent phagocytosis by macrophages (Kamanova, 
Kofronova et al. 2008). DNT is a cytoplasmic toxin with a size of 160 kDa able to 
induces necrosis (Cowell, Hewlett et al. 1979). It possesses glutaminase activity and can 
activate Rho GTPases (Schmidt, Goehring et al. 1999). In the toxin category is also 
included the tracheal toxin, although not regulated by BvgAS system. TCT is a 
disaccharide-tetrapeptide monomer of peptidoglycan (Cookson, Tyler et al. 1989) that 
impairs the respiratory epithelium inducing the production of Interleukin 1 and nitric 
oxide (Heiss, Moser et al. 1993). 
 
1.3  LONELY GUY AND CYTOKININS 
 
LONELY GUY (LOG) proteins are key enzymes in plants for the production of 
phytohormones named cytokinins. The gene encoding LOG was identified in a rice 
mutant in an attempt to screen for defects in shoot meristem activities (Kurakawa, Ueda 
et al. 2007). Since the flowers of these mutants often contained only one stamen but no 
pistil, for analogy the protein was named LONELY GUY. It is involved directly in the 
synthesis of cytokinins converting inactive cytokinins nucleotides to the biological 
active form by its phosphoribohydrolase activity (Kurakawa, Ueda et al. 2007). The 
active form of cytokinins is predominantly N6-substituted adenine derivatives. When the 
modified adenine is conjugated with sugar, such as in nucleosides and nucleotides, 
shows a minor or completely absent biological function in activating cytokinins 
receptors (Bajguz and Piotrowska 2009). LOGs hydrolyze the N-glycosidic linkage 
between the base and the ribose, leading to the formation of free active cytokinins. In 
plants these phytohormones are involved in many important physiological processes, 
such as growth and branching (Werner, Motyka et al. 2001), chloroplast development 
(Cortleven and Schmulling 2015), delay of leaf senescence (Gan and Amasino 1995) 
and activation of plant defense responses (Bari and Jones 2009).  
Over time the study of LOG proteins was limited, because they have been erroneously 
annotated as lysine decarboxylase enzymes (LDC) due to the presence of a highly 
conserved PGGxGTxxE motif (Kukimoto-Niino, Murayama et al. 2004, Jeon, Allard et 
al. 2006). Recently, some LOG-like proteins from non-plant organism, annotated as 
LDCs, have been identified to have phosphoribohydrolase activity and to produce 
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cytokinins (Dzurova, Forneris et al. 2015, Samanovic, Tu et al. 2015, Seo, Kim et al. 
2016). Indeed many plant-interacting microbes and fungi produce mis-annotated LOG 
proteins able to synthetize cytokinins (Hinsch, Vrabka et al. 2015, Radhika, Ueda et al. 
2015). These plant-like hormones are recognized by the plants and lead to a variation of 
resource allocation and to a morphological reconfiguration of the plant tissue that result 
in benefits for the pathogen. In fact the uncontrolled cytokinin signaling with the 
consequent delay of leaf senescence and creation of new organs such as galls and 
nodules, provides pathogens a continuous nutriment and protection against biotic and 
abiotic agents (Giron, Frago et al. 2013). Nevertheless a possible role of LOGs and their 
product cytokinins in a microbial cell-interaction has yet to be elucidated. Surprisingly 
cytokinin-activating homologous of plant LOG have been recently also identified in 
human pathogens Mycobacterium (M.) tuberculosis (Samanovic, Tu et al. 2015) and 
Pseudomonas aeruginosa PAO1 (Seo and Kim 2018). Interestingly, RV1205, the gene 
encoding M. tuberculosis LOG, was detected in an attempt to understand why the 
mycobacterial resistance to nitric oxide (NO) is linked to proteasome. Through a genetic 
screen in a proteasome-deficient strain, Rv1205 product was identified as proteasome 
regulated substrate and its accumulation in proteolysis mutants was responsible for NO 
sensitivity. In the absence of proteasome, which regulates and keeps LOG protein 
production to low levels, the amount of the cytokinins as well as of their breakdown 
products increase. In particular the cytokinin p-topolin degradation product para-
hydroxybenzaldehyde (pHBA) resulted to be lethal in proteolysis mutant of M. 
tuberculosis in presence of NO (Samanovic, Tu et al. 2015). Despite this, the 
physiological role of LOGs in mammalian pathogens and why they synthetize 
cytokinins are completely unknown so far. Few studies suggest that cytokinins may 
have suppressive effects on both innate and humoral immune responses (Lappas 2015) 
or may induce cellular differentiation or apoptosis in immune cells (Casati, Ottria et al. 
2011). Mammalian-pathogens, therefore, are likely able to reshape surrounding 
environment releasing plant-like cytokinins as modulator of the immune system. The 
specific effects that these metabolites may exert on immune cells depend on 
concentrations (Ciaglia, Pisanti et al. 2014). Another hypothesis is that LOGs may be 
involved in a signaling pathway at the inter-bacterial interface. However, a putative role 
of LOG protein during an infection is suggested by identification of a LOG homolog 
through a specific screen of genes expressed in a frog model of infection with M. 
marinum (Ramakrishnan, Federspiel et al. 2000).  
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The LOG domain is highly conserved among all kingdoms and this leads scientists to 
investigate new interesting research areas. Structural and molecular studies have 
proposed that the two highly conserved amino acids Glu and Arg, are the residues 
involved in the catalysis (Kukimoto-Niino, Murayama et al. 2004), the PGGxGTxxE 
motif holds the AMP moiety of substrate nucleotides (Seo, Kim et al. 2016) and that the 
active site needs two LOG domains for its formation (Seo, Kim et al. 2016). 
Notwithstanding these overall aspects, a phylogenetic analysis of LOG proteins from 
various organisms showed differences in the oligomeric state, in the amino acids of the 
binding site and variation at the PGGxGTxxE motif (Fig.2 A, B) (Seo and Kim 2017). 
According to this analysis it is possible to classify LOGs into at least two clusters based 
on the oligomeric state, the dimeric LOGs as type-I LOGs and the hexameric LOGs as 
type-II LOGs. Type-I and type-II LOGs may be in turn subdivided into two sub-groups, 
type-Ia and type-Ib, type-IIa and type-IIb respectively (Seo and Kim 2017). Type-II 
LOGs implement a hexameric form through an additional α-helix (Kukimoto-Niino, 
Murayama et al. 2004, Seo and Kim 2017).  The existence of two structural clusters 
further divided and variations in amino acids of the binding site suggest the presence of 
































Figure 3. Phylogenetic analysis and sequences alignment from various subtypes of LOG proteins in 
comparison. (A) Unrooted maximum likelihood phylogenetic tree of LOGs represented in a circular 
model. The four subgroups are schematized and marked with different colors: green for type-Ia and 
yellow for type-Ib, red for type-IIa and violet for type-IIb. Bootstrap values are shown at each node. (B) 
Amino acids sequence alignment of key residues of the four subgroup of LOG proteins involved in the 
PGGxGTxxE motif, catalysis and substrate binding. The oligomeric state of each LOG type is shown. 
Adapted from (Seo and Kim 2017).  
Dimeric LOGs 


















In order to defeat and prevent Pertussis disease, in the late 1940s was introduced the 
whole-cell pertussis (wP) vaccine, consisting of suspensions of killed B. pertussis 
organisms (Kuchar, Karlikowska-Skwarnik et al. 2016). The introduction of the vaccine 
led to a rapid reduction in both the incidence and the number of deaths caused by the 
infection. Because of its reactogenicity for the high number of endotoxins and 
comprehensive concerns about its safety, in the late of 1990s it was replaced with 
acellular pertussis (aP) vaccine in many developed countries (Kuchar, Karlikowska-
Skwarnik et al. 2016). aP is based by one to five purified antigens: PT, FHA, PRN and 
FIM 2/3. Unfortunately, notwithstanding a high vaccine coverage all over the world, an 
increase in pertussis cases has been recorded in adolescent and adults, concerning the 
public health about whooping cough resurgence. Although difficult to contextualize, 
several causes have been hypothesized, like waning immunity due to the lasting 
immunity induced by aP shorter than wP (Mooi, Van Der Maas et al. 2014), 
epidemiological changes in the circulating strains (Bart, Zeddeman et al. 2014, Bart, 
van der Heide et al. 2015) and the different both humoral and cell-mediated 
immunological response triggered by aP compared to the immunity generated by wP 
and natural infection (Higgs, Higgins et al. 2012). Furthermore, the difficulty of 
diagnosis in the first phase of the disease, leads to a loss of effectiveness of antibiotic 
treatment and, in severe cases, the patients may also not respond to the therapies due to 
breathing difficulties (Paddock, Sanden et al. 2008). The continuous increase of 
pertussis cases in all age groups is seriously worrying the public health, above all for the 
associated risk of transmission to incompletely or unimmunized infants. To solve this 
concern, the scientific community is operating on several fronts. On one hand it is 
trying to improve the current vaccine in order to have an acceptable safety, prevent 
transmission and provide a longer lasting immunity; on the other hand is trying to 
develop new therapeutic agents and targeted treatment strategies to reverse the disease 
at the time of diagnosis. However, to obtain all of these, it is necessary and 
indispensable to discover new features related to Bordetella pathogenesis and 
microbiology. On the basis of the observations above described, this PhD project aims 
to improve the knowledge of the physiology and pathology of Bordetella, which can 
help to improve the quality of vaccine and to develop alternative therapeutic 
interventions. Specific topics studied in this work were the following:  
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 Identification and characterization of the biochemical function of new selected 
proteins, potentially involved in Bordetella pathogenesis; 
 
 Identification of factors playing a key role in the complex communication circuit 
between the host and the pathogen. 
Concerning the aims, we focus our attention on protein pertussis BP1253, a putative 
















3.1  BIOINFORMATICS ANALYSIS 
 
The BLAST algorithm was used to investigate the sequence homologies between 
BP1253 and LOGs, while Cluster omega to realize amino acid sequence alignment with 
specific type-I and type-II LOGs. The structural analysis were performed through PDB 
Viewer, either to develop the modeling of BP1253 that to determinate the coordinates of 
atoms in the overlapping. To realize the figures, ESPript 3.0 software was used to 
represent the sequence alignment, instead, the graphic software PyMOL to visualize the 
overlaps. Regarding the phylogenetic tree, it was generated with MAFFT and figured 
through the software tool Archaeopteryx.js. 
 
3.2  BACTERIAL STRAINS AND GROWTH CONDITIONS 
 
The following B. pertussis strains were used in this study: Tohama I-derivative BP536 
(Weiss and Falkow 1983 153, 304-9), the clinical isolates B3629, B3621. Bacteria were 
stored at -80 °C and recovered by plating on Bordet-Gengou (BG) agar plates, 
supplemented with 15% (v/v) sheep blood, for 3 days at 37°C. Bacteria were then 
inoculated at initial 600 nm optical density (OD600) of 0.05–0.1 in Stainer-Scholte 
medium supplemented with 0.4% (w/v) L-cysteine monohydrochloride, 0.1% (w/v) 
FeSO4, 0.2% (w/v) ascorbic acid, 0.04% (w/v) nicotinic acid, 1% (w/v) reduced 
glutathione. Cultures were grown in rotary shakers at 37 °C. 
 
3.3  GENERATION OF E. COLI EXPRESSING RECOMBINANT BP1253 
PROTEIN AND PURIFICATION PROCEDURE 
 
The synthetic gene1253 from Bordetella pertussis was synthesized and assembled by 
GeneArt (Thermofisher) starting from synthetic oligonucleotides and/or PCR products. 
The fragment was inserted into pET24b(+)_D455 as a fusion construct with a carboxyl-
terminal 6x histidine tag separated from the last amino-acid of the protein by a linker of 
2 amino-acid residues. The plasmid DNA was purified from transformed bacteria and 
concentration determined by UV spectroscopy. The sequence congruence verified by 
sequencing of the final construct within the insertion sites was 100%. Escherichia coli 
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strain BL21 (DE3) cells (New England Biolabs) were transformed with the above 
construct and used for protein expression. Cells were grown using BioSilta medium 
(Enpresso B Animal-free growth systems), at 30°C for 8 h with gentle shaking (160 
rpm). The expression of Bp1253 gene was induced to an A600 of 0.5–0.6 by the addition 
of 1mM isopropyl β-D-1-thiogalactopyranoside (IPTG) 24 h at 17°C. Cells were 
harvested by centrifugation and re-suspended in lysis buffer containing 50 mM 
NaH2PO4, 300 mM NaCl, pH 7.4 and protease inhibitor EDTA free (Boheringer 
Mannheim) at a ratio of 10 ml of lysis buffer per 1 g of bacterial pellet. After lysis, 
performed via sonication (Qsonica Q700), cell lysates were clarified by centrifugation 
at 15000 x g for 50 min at 4°C, and the supernatant, containing the expressed protein, 
filtered using a 0.22 μm membrane filters (EMD Millipore filters) before starting the 
first chromatography step. BP1253 was purified by a Co2+-affinity chromatography 
(5mL HiTrap TALON crude, GE Healthcare) at room temperature (RT, 25°C) using an 
AKTA purifier 100 system (GE Healthcare). The column was equilibrated with buffer 
A (50 mM Tris pH 8, 300 mM NaCl). After loading the crude extract, the column was 
washed with 10 bed volumes of buffer A. Bound proteins were eluted with buffer A 
containing 500 mM imidazole. The content of lipopolysaccharide (LPS) on the purified 
protein was checked using the Endosafe nexgen-PTS system (Charles River). When the 
content of LPS was out of the range it was removed using the EndoTrap Red columns 
(Hyglos). The purity of the protein was checked using 4–12% SDS–PAGE gradient gels 
in MES buffer, after the identification of the fractions containing BP1253, samples were 
pooled and stored at -20°C for subsequent analysis. 
 
3.4  SIZE-EXCLUSION CHROMATOGRAPHIC ANALYSIS 
 
The investigation of BP1253 oligomerization was performed using an analytical size-
exclusion chromatography. The chromatographic step was performed using a BEH200 
column 4.6x300mm (Waters) at a Flow of 0.4 ml/min with a buffer containing 10 mM 
NaH2PO4 and 400 mM (NH4)2SO4 pH 6.0. Protein samples of 15 µl 0.62 mg/ml and 3 
mg/ml were analyzed. The molecular weights of the different forms of BP1253 were 





3.5  MULTI-ANGLE LIGHT SCATTERING 
 
Multi-Angle Light Scattering (MALS) analysis was performed in an HELEOS 
(WYATT Technology) in combination with a SEC separation. SEC was carried out 
with Sepax Zenix SEC-300 3 mm 7.8 x 300 mm at a flow of 0.5 ml/min with PBS as 
running buffer. The BP1253 for the analysis was diluted in PBS buffer at a final 
concentration of 0.6 mg/ml. Results were analyzed using the ASTRA software 3.1. 
 
3.6  GENERATION OF THE BP1253 KNOCKOUT STRAIN 
 
The deletion strain for the genes BP1251-1252-1253 of the B. pertussis BP536 Tohama 
I-derivative was constructed as follows. The 5′ and 3′ extremities of the locus were 
amplified by PCR using Bp chromosome as template and the oligonucleotides  
FlankingUP-Fw ccgGAATTCCGAAAACCGTAGCGGTCGAA and  
FlankingUP-rev ggaGGATCCGGACCGATGTCGGCCAATTT,  
FlankingDOWN-Fw ggaGGATCCCGCGTCTATGTCGACCACG and  
FlankingDOWN-rev cccAAGCTTCGAACTGCACCTGACCATCC as primers, 
respectively.  
The amplicons were then successively introduced as EcoRI-BamHI and BamHI-HindIII 
fragments into pUC19, together with a BamHI-BamHI fragment encoding the 
kanamycin resistance cassette for selection. The resulting EcoRI-HindIII fragment was 
then purified and introduced into the EcoRI-HindIII sites of pSORTP1, a mobilizable 
suicide plasmid used for conjugation between Bp and E. coli. Conjugation was 
performed on BG-blood agar plates containing 10 mg/ml MgCl2 for 5 hours, and co-
integrates were selected on BG-blood agar plates containing 10 µg/ml gentamicin and 
20 µg/ml nalidixic acid to prevent growth of the E. coli donor. Single crossing overs 
determine the insertion of the pSORTP1 vector in the chromosome and confer 
gentamicin resistance and streptomycin sensitivity. Double crossing overs were selected 
by a successive step on BH-blood plates containing 25 µg/ml of kanamycin and 400 
µg/ml of streptomycin. After 3 to 4 days growth on selective media, isolated kanamycin 




3.7  HIGH-THROUGHPUT PURIFICATION OF BP1253 MUTANTS 
 
Single point conservative and not conservative mutations were inserted into the Bp1253 
gene to generate six different mutants. Mutated genes were synthesized and assembled 
by GeneArt (Thermofisher) starting from synthetic oligonucleotides and/or PCR 
products using the same plasmid and procedure as above described. The mutants 
generated were R120A, R120K, K121A, K121R, E143A and E143D. Purification of 
mutants was performed under vacuum conditions in a 96-well Vacuum plate. Cells were 
lysed using B-PER (Sigma) and applied on a His Multitrap HP 50ml NiSepharose High 
Performance 96 wells previously washed with water and equilibration buffer (300 mM 
NaCl, 50 mM NaH2PO4, pH 8). After loading the samples, the plate was washed with 
80 vol. of washing buffer (300 mM NaCl, 50 mM NaH2PO4, 20 mM imidazole, pH 8) at 
room temperature. The His-fusion proteins were eluted in two steps by addition of 6 
vol. of elution buffer (300 mM NaCl, 50 mM NaH2PO4, 500 mM imidazole, pH 8) 
twice. All the elutions related to the same protein were subsequently pooled. All 
purification steps were executed applying a vacuum not exceeding the maximum 
pressure of 5 mmHg. 
 
3.8  SDS-PAGE AND WESTERN BLOT 
 
SDS-PAGE and western blot (WB) analyses were performed to monitor expression, 
purity and identity of BP1253 during purification. Samples mixed with 1X NuPage LDS 
loading buffer and 1X NuPage Sample reducing agent (Life Technologies), were heated 
at 70°C for 10 minutes before loading 20 μl of the mixture onto a 4-12% gradient 
NuPAGE Bis-Tris gel (Life Technologies). SeeBlue Plus Prestained Standard markers 
were run onto each gel, which was stained with Comassie Blue to visualize the proteins. 
Separated proteins were electro-transferred onto nitrocellulose membranes with iBlot 2 
Dry Blotting System (Life Technologies). The membranes were blocked for 60 min 
with 0.1% Tween 20 and 10 % milk in phosphate buffer solution (PBS), incubated for 1 
hour with specific mouse polyclonal α-BP1253 antibodies (1:500 dilution) in 0.1% 
Tween-20 and 3% milk buffer in PBS. After three washes with 0.1% Tween-20 in PBS 
(T-PBS) the membrane was incubated with a secondary rabbit α-mouse horseradish 
peroxidase conjugated antibody (Jakson Immune Research Laboratory, 1:1000 
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dilution), for 30 min at room temperature. Bound antibodies were visualized, after 
washings membranes thrice with T-PBS, with ECL immunoblotting detection system 
(Amersham) according to the manufacturer’s instructions. The supernatants of the 
clinical isolates were previously TCA precipitated before western blot analysis. Briefly, 
the supernatants were incubated 10 min at 4°C with 20% TCA and then centrifuged at 
14000 x g for 5 min. The pellets were washed twice with 200 μl of cold acetone to 
remove TCA. After washings, pellets were dried in heat block for 10 min to dry off 
acetone. 
 
3.9  PHOSPHORIBOHYDROLASE ACTIVITY ASSAY 
 
Phosphoribohydrolase activity was assessed by detecting the nitrogenous base ring 
compounds after separation with a thin layer chromatography (TLC) as described (Seo, 
Kim et al. 2016 6, 31390). Briefly, enzyme reaction was carried out in a mixture 
containing, in a final volume of 20 µl, 40 mM Tris-HCl (pH 8), 20 mM Nucleotide 
Mono Phosphate (NMP) as substrate and the amount of purified recombinant protein as 
specified in figure legends. After incubation at 30°C, samples (5 µl) were denatured at 
95°C for 2 min and then 1 µl dotted on PEI-Cellulose-F-plastic TLC sheet (Merck 
Millipore). Since the solubility of guanine is poor in water and to enhance its visibility 
on TLC, the inactivation was performed with 1 M NaOH (v/v). The nitrogenous base 
ring was separated from the phosphoribosyl moiety using a TLC method with a mobile 
phase containing 1 M sodium chloride except for pyrimidine rings where the mobile 
phase was acetone/water 30/70 (v/v) with the addition of 0.2 mol/l NaCl. After the run, 
the sheet was completely dried and the separated dots visualized by UV lamp (264 nm). 
 
3.10  GENERATION OF MOUSE IMMUNE SERA 
 
BALB/c mice (10 females/group, 6-week old) (Charles River Laboratories International 
Inc., Wilmington, MA) received three intraperitoneal immunizations, with a 4-week 
interval, with aluminum hydroxide (2 mg/ml) adjuvanted recombinant BP1253-His (10 
µg per dose) at one fifth of a human dose. Sera were collected before immunization and 
2 weeks after the third immunization. Control mice immunized with adjuvant only were 
included in the experiments. All the experiments involving animal were performed in 
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compliance with the Italian law with the approval of the local Animal Welfare Body 
(AWB 2014/06) followed by authorization of Italian Ministry of Health. 
 
3.11  SURFACE PLASMON RESONANCE EXPERIMENTS (BIACORE) 
 
SPR experiments were performed using a Biacore T200 instrument (GE Healthcare). 
The recombinant BP1253 protein was amine-coupled at 20 µg/mL in 50 mM NaOAc at 
pH 4.5 to the surface of a CM5 sensor chip (GE-Healthcare), activated with 50 mM 1-
ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) / 50 mM N-hydroxysuccinimide 
(NHS). Typically, response levels of 8000-9000 RU were achieved.  After priming the 
system with HBS-EP+ buffer (10 mM HEPES; 150 mM NaCl; 3 mM EDTA; 0.05% 
Surfactant P20; pH 7.4), affinity data were generated under steady state conditions, 
injecting ligand nucleotides dissolved in HBS-EP+ at 30 µl/s and 25°C for 60 s, then 
allowing to dissociate for another 60 s. Blank-subtracted sensorgrams were analyzed 
using the Biacore T200 Evaluation Software v. 3.0. Response values were evaluated 4 
seconds before the end of each injection and averaged over a window of 5 sec. 
 
3.12  IDENTIFICATION AND CHARACTERIZATION OF CYTOKININS 
BY LC-MS/MS 
 
For the analysis of the cytokinins, the supernatant was obtained spinning down 40 ml 
bacterial growth broth at 9000 x g for 20 min. filtered and treated as described (Dobrev, 
Hoyerova et al. 2017 1569, 31-39). Briefly, the supernatant was cleared by molecules 
with MW higher than 3kDa using a protein concentrator 3K (Amicon) following 
vendor’s instructions. Subsequently the samples were concentrated up to 1 ml volume 
through a Speed Vac and loaded on a solid phase extraction (SPE) column (MCX 
matrix, Oasis). Before loading, samples were previously acidified to pH 3 with formic 
acid. The column was then washed with 0.5 mL SPE load solvent (1 M formic acid), 
followed by 1 mL water. The samples of interest were eluted with 0.5 mL of freshly 
prepared solvent 2 (0.35 M ammonium hydroxide in 70 % methanol, to 70 mL 
methanol were added 2.5 mL of 25% ammonium hydroxide filled to 100 mL with 
distilled water) and the flow-through collected into new 2 mL microcentrifuge tube was 
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dried in SpeedVac at 10 mBar and 40 °C. The dried fractions were stored at −20 °C 
until LC-MS analysis. At the time of starting the analysis in LC-MS, the dried samples 
were dissolved into 100 μL 5 % methanol in water and centrifuged at 20000 × g, 4 °C 
for 20 min. The supernatant was transferred into an autosampler vial and used for the 
analysis without further modification. LC-MS/MS analysis was performed using an 
LTQ-Orbitrap XL coupled with an Ultimate 3000 HPLC system equipped with a 
reverse phase column Luna C18 (2) 100mm x 2mm, 3 µm, 100 Å. The mobile phase A 
and B used for the analysis of the sample were 0.1% formic acid in water and 0.1% 
formic acid in acetonitrile respectively. The gradient started with 100% of A, 
maintained for 3 minutes and the phase B increased up to 20% in 12 minutes. Then after 
two minutes the phase B reached the 100% and it was hold constant for two minutes. 
The flow rate was set to 200 µl/min., UV at 268 nm, while a positive ion mode with 
electrospray was used as mass spectrometric detection. The ESI ion source spray 
voltage was set to 5 kV, the capillary temperature was 300 °C, tube lens and capillary 
voltage were 110 and 35 V respectively. The sheat and auxiliary gas (N2) were set to 20 
and 5 a.u., respectively. The mass spectra and the MS/MS spectra were recorded using 
the data dependent scan mode at resolution of 30000, while the fragmentation mass 
spectra were recorded in low resolution with collision energy 25 a.u. 
 
3.13  PHENOTYPIC CHARACTERIZATION 
 
Bacteria stored with glycerol were inoculated at initial 600 nm optical density (OD600) 
of 0.05–0.1 in Stainer-Scholte medium supplemented with 0.4% (w/v) L-cysteine 
monohydrochloride, 0.1% (w/v) FeSO4, 0.2% (w/v) ascorbic acid, 0.04% (w/v) 
nicotinic acid, 1% (w/v) and reduced glutathione. Cultures were grown in rotary shakers 
at 37 °C for 24 h. After that we tested the bacterial susceptibility to oxidative stress by 
treating cultures with 0.1 and 0.3 M H2O2 (Sigma) for 30 minutes as specified in Figure 
legend. The viability of the Bp strains was measured after treatment. 
 
3.14  STATISTICAL ANALYSIS 
 
Data are presented as the means ± SD and the Kruskal-Wallis test was used to analyze 
significance of data. Values of P ≤ 0.05 were considered and referred to as significant. 
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3.15  PROTEIN ASSAY 
 
Protein concentration was measured with the bicinchoninic acid (BCA) protein assay 
(Smith, Krohn et al. 1985 150, 76-85) (Thermo Scientific-Pierce, Rockford, IL, USA), 

















4.1  PRODUCTION AND PURIFICATION OF 
RECOMBINANT BP1253 
 
In order to obtain the Bp protein BP1253, we transformed BL21 (DE3) competent E. 
coli cells with known concentrations of pET24b(+)_D455 plasmid containing the 
corresponding synthetic gene. BP1253 was expressed as His-tagged recombinant 
protein after IPTG induction and purified by a single chromatographic step on an 
immobilized metal (Co2+) affinity chromatography. SDS-PAGE analysis gave a single 
pure band (Fig. 4A) and western immunoblot (Fig. 4B) confirmed the identity of the 
purified protein, instead the MS analysis of BP1253-His, resulted in an experimental 
mass of 24872.53 Da (Fig 4C). Due to overexpression in the bacterial system, not all the 
methionine residues of the recombinant protein have been removed from the proteins 














Figure 4. Expression, purification and BP1253 identification. BP1253 was cloned in E. Coli BL21 
(DE3) and purified after IPTG induction trough HiTrap TALON crude. (A) The eluate, 2 µg, was 
evaluated by SDS-PAGE in 4-12% gradient NuPAGE Bis-Tris gel stained with Coomassie Blue. 
Molecular mass markers (kDa) are indicated on the left (B) The identity of the purified protein was 
further confirmed by immunoblot. The experiment was performed with 25 ng of BP1253 and with mouse 
polyclonal α-BP1253 (1:500 dilution) as described in Material and methods. Molecular weights of 
proteins markers are shown on the left. (C) Intact mass measurement revealed a BP1253-His molecular 
weight of 24872.53 Da. The weight of 25003.64 Da refers to BP1253-His proteins with unremoved 
methionine. 






To characterize the functional unit and the oligomeric state of BP1253, we performed a 
size exclusion chromatography (SEC) (Fig. 5). The SEC gave a main peak with a 
retention time of 7.20 minutes. Using the molecular weights and the retention times of 
the protein standards, through a graphic interpolation we calculated that this peak refers 
to a molecule of about 50 kDa. The analysis revealed also a second, but very small peak 
approximately of about 100 kDa. To exclude the hypothesis that the oligomeric state of 
the protein depended on the concentration, we performed SEC analysis with two 
different concentrations of BP1253, 0.6 mg/ml and 3 mg/ml respectively. The two 
chromatograms acquired did not display any differences to each other suggesting that 











Figure 5. BP1253 is a dimer in size-exclusion chromatography. BP1253 was eluted as dimeric form 
with a molecular weight of 50 kDa. The analysis was carried out with concentrations of 0.6 mg/ml and 3 
mg/ml of protein. The peak corresponding to BP1253 is marked in black, while the proteins standards 
with their own molecular weights are highlighted in blue. The figure refers to 3 mg/ml protein 
concentration. 
 
To consolidate the results obtained in SEC, we performed a multi-angle light scattering 
(MALS) study (Fig. 6). This analysis showed further the presence of a protein with a 
molecular weight of 49.32 (±5%) kDa with a polydispersity of 1.010 (±7.7%). MALS 
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Figure 6. Multi-Angle Light Scattering confirms the dimeric state of BP1253. MALS analysis 
confirmed the dimer as the oligomeric state of BP1253. The study was performed in combination with 
SEC using a final protein concentration of 0.6 mg/ml. The data were analyzed with ASTRA software 3.1. 
 
 
4.2  IN SILICO-BASED IDENTIFICATION OF BP1253 AS A 
MEMBER OF THE LONELY GUY FAMILY 
 
Recently, in the literature it has emerged that many proteins from different organisms of 
various kingdoms, like Plantae, Animalia, Bacteria and Fungi, are mis-annotated as 
lysine decarboxylase because the presence of PGGxGTxxE motif in their sequence 
(Naseem, Bencurova et al. 2018). A more accurate analysis classifies them as members 
of the LOG protein family. This mis-annotated classification included also BP1253 
considered a possible LDC so far. Through bioinformatics analysis and following 
sequence alignments we observed that BP1253 shares with LOG proteins not only the 
highly conserved motif PGGxGTxxE, but also the catalytic core complying with the 



























Figure 7. Sequence alignment between LOG proteins from various subtypes and BP1253. Primary 
structures alignment among LOG proteins type-I and type-II and BP1253 was generated by Cluster 
omega and drawn with ESPript 3.0 software. The residues involved in the catalysis are indicated with 
green-colored stars while, the amino acids that accommodate AMP in the catalytic site are indicated by 
orange-colored triangles. The PGGxGTxxE motif is specified by a blue bracket. The amino acids shared 
by all the LOG proteins are highlighted in red. MtLOG, PaLOG and AtLOG, are abbreviations of type-I 
LOG proteins from M. tuberculosis, P. aeruginosa and A. Thaliana. CgLOG, ScLOG and TtLOG are 
abbreviated name of type-II LOGs from C. glutamicum, S. coelicor and T. thermophiles. 
 
We also noticed from sequence alignment, that BP1253 presents a higher sequence 
homology towards the LOGs type-II than the LOGs type-I. As described, the cluster 
type-II of LOG proteins assembles phosphoribohydrolase enzymes with a hexameric 
form, but we demonstrated (Fig. 5, 6) that the oligomeric state of BP1253 is dimeric. A 
phylogenetic tree between BP1253 and proteins described in literature to possess 
phosphoribohydrolase activity and classified as type-I or type-II, indicates how our 

















Figure 8. Likelihood phylogenetic tree between described LOGs and Bordetella pertussis BP1253. 
The phylogenetic tree was realized with MAFFT and visualized through the software tool 
Archaeopteryx.js. BP1253 is highlighted in green. The proteins are divided in two branches; one 
represents type-I LOGs while the other one the type-II LOGs. The dimeric BP1253 is grouped with Type-
II LOGs characterized by having a hexameric form. 
 
 
4.3  BP1253 BINDS NUCLEOTIDES 
 
LOG proteins bind and cleave preferentially adenosine 5'-monophosphate (AMP). To 
verify whether BP1253 is able to bind AMP like the known LONELY GUY proteins, 
we at first resorted to a theoretical approach overlapping a modeling of BP1253 with a 
monomer of a Mycobacterium marinum protein classified in the maximum likelihood 
phylogenetic tree (Seo and Kim 2017) (Fig. 9) as type-I LOG protein with dimeric form 
(MmLOG). Characteristic of this M. marinum protein with PDB ID 3SBX is that it was 
crystallized in complex with AMP (Baugh, Phan et al. 2015). The modeling was based 
on a monomer of Thermus Thermophilus protein TT1465 (TtLOG), PDB ID 1WEK, 
with which BP1253 shares the 48% of homology. TT1465 is annotated in the 





Squared (RMS) value between 0 – 2Å. In this case the overlap produced a RMS value 
















Figure 9. Overlapping between monomer structures of MmLOG and a modeling of BP1253. The 
prediction data obtained from the overlapping gave a RMS value of 1.21 Å and showed the analogy of the 
two binding sites. The modeling was created through PDB Viewer on the base of 48% homology among 
BP1253 and TtLOG sequences. The overlapping was realized with PDB Viewer and the figures of single 
monomers and of overlaps were created via the graphic software PyMOL. 
 
To validate definitively the capability of BP1253 to bind AMP, we performed surface 
plasmon resonance (SPR) studies. Recombinant BP1253-His was immobilized on the 
surface of a golden chip CM5 and a ranging concentration from 0.78 to 400 μM of 
AMP was applied to measure the dissociation constant (kd). Analysis by Biacore 
indicated that BP1253 binds AMP with a kd of 5.7 µM (Fig. 10) suggesting a high 

















Figure 10. Surface plasmon resonance study with AMP. Biacore analysis displays that BP1253 has the 
ability to bind AMP with a dissociation constant of 5.7 µM. BP1253-His was immobilized via amine 
coupling procedure on Sensor chip CM5. Concentrations from 0.78 to 400 μM were used to measure the 
kd. The results shown are representative of three independent experiments giving identical results. 
 
To investigate if this protein is able to bind other monophosphate nucleotides, both 
purines and pyrimidines such as GMP, IMP, CMP, TMP and UMP were analyzed. 
Results shown in Fig. 11 indicate that both GMP and IMP are able to bind BP1253 with 
kd of 38 µM and 71.8 µM respectively; a lower affinity was obtained with TMP and 











Figure 11. Biacore analysis of GMP and IMP. SPR studies between BP1253 and various 
monophosphate nucleotides revealed the BP1253 capability to bind GMP and IMP with good affinity. For 














Table I. Purines and pyrimidines analyzed in surface plasmon resonance studies. List of 
monophosphate nucleotides evaluated by Biacore on BP1253 and the related kd. 
 
The binding experiment was then extended to other nucleotide metabolites (Tab. II). 
Among them NAD, NADH and NADP revealed a kd of 0.3 µM for NAD, 0.4 µM for 
NADH and 4.4 µM for NADP (Fig. 12). For the other substrates a very high kd or no 










Figure 12. Biacore analysis of nucleotide metabolites. SPR investigations performed on nucleotide 
substrates NAD, NADH and NADP using Sensor chip CM5 and concentration of substrates from 0.097 to 








AMP 5.7 µM 
GMP 38 µM 
IMP 71.8 µM 
TMP 2.4 mM 




















Table II. List of nucleotide metabolites investigated in SPR studies. 
 
 
4.4  BP1253 HAS PHOSPHORIBOHYDROLASE ACTIVITY 
 
LONELY GUY catalytic activity consists in the hydrolysis of the N-glycosidic linkage 
between the N6-modified adenine and ribose 5’-monophosphate, leading to the 









Figure 13. Schematic representation of phosphoribohydrolase catalyzed reaction. 
    Nucleotide metabolites 
 
NAD Nicotinamide adenine dinucleotide 
NADH Nicotinamide adenine dinucleotide reduced 
NADP Nicotinamide adenine dinucleotide phosphate 
α-NAD α-Nicotinamide adenine dinucleotide 
ε-AMP ε-Adenosine monophosphate 
ADPR Adenosine diphosphoribose 
ATP Adenosine triphosphate 
NGD Nicotinamide guanine dinucleotide 
GTP Guanosine triphosphate 
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Sequence alignments with LOG proteins showed that BP1253 has a high amino acid 
sequence identity with type-II LOGs and that shares with all of them the PGGxGTxxE 
motif and the catalytic residues. Additionally, the SPR analysis revealed the capability 
of the pertussis protein to bind AMP. These results led us to hypothesize that BP1253 
could be a LOG protein. To examine the biochemical activity of BP1253, we performed 
phosphoribohydrolase activity assay. As substrate we used AMP, described to be the 
preferred substrate of LOG (Samanovic, Tu et al. 2015, Seo, Kim et al. 2016, Seo and 
Kim 2017, Seo and Kim 2018, Seo and Kim 2018). AMP and the product of the 
reaction adenine run at different height for their different hydrophilicity on TLC and are 
visible as spots under UV light at 264 nm. In dose-response experiment AMP was 
incubated at 30°C with different concentration of the protein and the reaction resulted 
BP1253 dose-dependent as shown in Fig 14 A. In the time course experiment, the 
substrate was incubated with 24 µM of enzyme and the reaction stopped at different 
time points. It resulted that the catalytic activity increased over the time (Fig.14 B). As 










Figure 14. Dose-response and time-course experiments reveal phosphoribohydrolase activity in 
BP1253. The experiments were performed at 30°C in the presence of 20 mM AMP as substrate. After 
heat inactivation of the protein at 95°C for 2 min, the products were separated by TLC in 1 M NaCl using 
Cellulose F plastic sheets. The dots were evidenced under UV light at 264 nm. (A) Dose-response 
experiments carried out after 6 hours of incubation. The BP1253 concentrations used were 6, 12, 24 and 
48 µM. (B) Time course assay carried out with 24 µM of enzyme at different incubation time. (C) TLC 
with the heat-inactivated protein as negative control performed after 8 hours of incubation. 
 
A B C 
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Since the SPR study for GMP resulted in a dissociation constant of 38 µM comparable 
to that of AMP, in order to investigate if BP1253 is able to cleave the N-glyosidic 











Figure 15. GMP is cleaved by BP1253. The assays were performed at 30°C in the presence of 20 mM 
GMP. To improve the solubility of GMP, the inactivation was performed with 1 M NaOH (v/v) and then 
the products of reaction separated by TLC in 1 M NaCl using Cellulose F plastic sheets. The dots were 
visible under UV light at 264 nm. (A) Dose-response experiments carried out in 20 minutes. 1.2, 2.4 and 
4.8 µM were the enzymatic concentrations used for the assay (B) Time course experiment performed with 
2.4 µM of BP1253 at different incubation time.  
 
As clearly shown in Fig. 15, BP1253 recognizes GMP as substrate showing 
phosphoribohydrolase activity. Of note in the assays with GMP we used a 10-fold lower 
concentration of enzyme compared to that one used for the AMP. The substrate was 
almost completely hydrolyzed after 30 minutes of incubation indicating GMP a 
substrate more efficient compared to AMP for BP1253. For a more complete 
characterization of BP1253 we examined the protein activity with several 
ribonucleotides and deoxyribonucleotides (Tab. III). Among them a high 
phosphoribohydrolase activity was recorded also for CMP (Fig. 16). This partially 
explains the high kd measured by biacore for CMP, the substrate is so fast cleaved that 








































Nucleotides 20 minutes 24 hours 
AMP - + 
GMP ++ ++ 
IMP + ++ 
CMP ++ ++ 
TMP - + 
UMP - - 
dAMP - - 
dGMP - + 
dCMP + ++ 
dTMP - + 
dUMP + ++ 
Figure 16. BP1253 cleaves CMP. The assay was carried 
out at 30°C in the presence of 20 mM CMP for 20 
minutes. The inactivation was performed at 95°C for 2 
min. To separate the products by TLC on Cellulose F 
plastic sheets the mobile phase was acetone/water 30/70 
(v/v) with the addition of 0.2 mol/l NaCl. The dots were 
visible under UV light at 264 nm.  
Table III. Ribonucleotides and 
deoxyribonucleotides tested with 
BP1253 in phosphoribohydrolase 
assay. The different nucleotide 
substrates were incubated with 2.4 µM 
of BP1253 for 20 minutes and 24 hours 
at 30°C. The reaction was blocked with 
1 M NaOH for those compounds 
having guanine as nitrogen base, whilst 
by heat at 95°C for 2 minutes for the 
others. The products were separated by 
TLC on Cellulose F plastic sheets. We 
used as mobile phase 1 M NaCl for 
purine separation while, the mobile 
phase for pyrimidines was 
acetone/water 30/70 (v/v) with the 
addition of 0.2 mol/l NaCl. The dots 
were visualized under UV light at 264 
nm. We registered different activities 
from BP1253 depending on the 
incubated substrates. We indicate with - 
those reactions for which no 
phosphoribohydrolase activity was 
recorded, as + we specify reactions 
with a minimal activity, as ++ we 
identify high catalytic activity. 
42 
 
As previously described BP1253 contains the typical amino acids of LOG catalytic 
core. Therefore, to probe if the R120, E143 residues and K121 probably involved in 
substrate binding, may have a role in enzymatic activity, we generated by site-specific 
mutagenesis a panel of recombinant BP1253 mutant proteins. In these single point 
mutants R120, E143 and K121 were changed first with Ala and then with the 
conservative amino acid: Lys, Asp and Arg respectively. Among the amino acids 
implicated in the binding, we chose the K121 residue for its closeness to the catalytic 
amino acid R120. The mutants were expressed as His-tagged recombinant proteins in 
BL21 competent E. coli and purified by two step of high-throughput immobilized metal 
(Ni2+) affinity chromatography. SDS-PAGE analysis and western immunoblotting 








Figure 17. Purification profile of BP1253 mutants. BP1253 variants with specific site mutations with 
non-conservative and conservative amino acids were cloned in E. Coli BL21 (DE3) and purified in high-
throughput through a His Multitrap HP 96-well Vacuum plate after IPTG induction. (A) SDS-PAGE (2 
µg of proteins) and Immunoblotting (20 ng of proteins) performed on R120A, K121A and E143A. Mouse 
polyclonal α-BP1253 (1:500) was used as the primary antibody. Molecular weights of proteins markers 
are shown on the left. (B) SDS-PAGE (2 µg of proteins) and Immunoblotting (20 ng of proteins) carried 
out on R120K, K121R and E143D. Molecular mass markers (kDa) are indicated on the left and the mouse 
polyclonal α-BP1253 (1:500) was used for the WB analysis. 
 
After purification, we tested the R120A, K121A and E143A mutant proteins with the 
substrates GMP (Fig. 18 A, B panel) and CMP (Fig. 18 E, F panel) in 
phosphoribohydrolase assays at 20 and 40 minutes. The non-conservative amino acid 
substitutions resulted in a complete loss of the enzymatic activity. When we tested 










the replacement of K with R at the residue 121 produced a minimal hydrolysis with 
GMP and CMP as substrates though not comparable to wild type (Fig. 18 C, D, G, H). 
These results confirm that Arg 120 and Glu 143 are the catalytic residues implicated in 
the phosphoribohydrolase activity and that the positive charge of the K at 121 residue is 
essential for the catalysis. AMP was assayed with conservative mutants for a time of 6 
and 18 hours (Fig. 18 I, J). Also in these cases, R120K and E143D replacements caused 
the loss of the enzymatic activity and, K121R a hydrolysis almost undetectable on TLC. 
The results from the mutagenesis are in agreement with the recently described LOG 
proteins and this confirms that BP1253 is a member of the LOG family and, henceforth, 























































Figure 18. Phosphoribohydrolase activity assays with recombinant BP1253 mutant proteins. The 
experiments were all performed at 30°C in the presence of 20 mM of substrate. The incubation time was 
20 and 40 minutes for GMP and CMP, and 6 and 18 hours for AMP. The reaction was blocked by heat 
inactivation for enzymes incubated with CMP and AMP and, with 1 M NaOH (v/v) for the proteins 
incubated with GMP. The products were separated by TLC on Cellulose F plastic sheets and the mobile 
phase was NaCl for purine and acetone/water 30/70 (v/v) with the addition of 0.2 mol/l NaCl for CMP. 
The dots were evidenced under UV light at 264 nm. As positive control we used wild type BP1253. (A) 
Non-conservative mutations incubated with GMP for 20 minutes and (B) for 40 minutes. (C) 
Conservative substitutions assayed with GMP for 20 minutes and (D) 40 minutes. (E) Alanine 
substitutions tested with CMP for 20 minutes and (F) for 40 minutes. (G) Conservative mutants assessed 
with CMP for 20 minutes and (H) 40 minutes. (I) Conservative replacements incubated with AMP for 6 






4.5  BpLOG SYNTHESIZES 6-O-METHYLGUANINE 
 
BpLOG being a member of the LOG family and in analogy with its homologous 
proteins should be able to produce cytokinins. Therefore, we decided to try to identify 
the physiological product of BpLOG. For this purpose, we generated from Tohama I-
derivative BP536 a Bordetella strain deleted of the operon in which is located Bp1253 
gene in order to compare the production of cytokinins between the wild type strain and 
the knockout. (Bp1253 gene is located inside an operon along with other two genes, 
Bp1251 and Bp1252 that encode for a putative toxin and putative exported protein 
respectively. However, currently, the real function of both proteins is unknown). The 
attempt of this investigation is to identify the produced cytokinins by the two strains, to 
separate them in reverse phase through HPLC and to visualize them as peaks via UV 
detector exploiting the intrinsic capability of these compounds to adsorb UV light. In 
plants the cytokinins are hormones, therefore, they are produced in small quantities and 
released in the extracellular space. For this reason, we focused our attention first on 
supernatant. The knockout and the wild type strains were grown in Stainer-Scholte 
medium at 37°C until 48 hours, after that the supernatants were filtered, cleared by 
proteins and molecules with molecular weight higher than cytokinins as described in 
Methods (Dobrev, Hoyerova et al. 2017). At the end of the purification procedure, the 
dried samples, re-suspended in 100 μL 5 % methanol were run in HPLC and analyzed in 
MS. The two chromatographic spectra related to Tohama I strain supernatant and to 
Δ1253 supernatant arising from UV detector were identical, but we observed that at 
retention time of 5 minutes in wild type spectrum there was a small peak completely 
absent in Δ1253 (Fig. 19). This peak was isolated and analyzed in MS. It turned out that 
this peak corresponded to a compound with molecular weight of 165 Da, 166 Da in the 
mass chromatogram because of electrospray with a positive ion mode used as mass 
spectrometric detection, and with an apparent molecular formula of C6H7N5O. In data 
banks the compound with this molecular formula that fitted better with our study was 
the 6-O-Methylguanine. We tested it on HPLC at the same conditions used for 
supernatants samples and noted that the retention time of 6-O-Methylguanine was very 





Figure 19. LC-MS analysis of BpLOG physiological product. LC investigations revealed at 268 nm 
the presence of a peak in Tohama I growth medium utterly absent in the medium of knockout strain. This 
peak isolated and analyzed in mass spectrometry in a positive ion mode with electrospray resulted in a 
compound of 166 Da with a putative molecular formula similar to that of 6-O-Methylguanine. The 
standard was run on HPLC and the retention time was similar to physiological product. The purification 
of cytokinins was performed by solid phase extraction with a MCX matrix after that the growth medium 
was filtered with a membrane 3K, the volumes reduced at 4 ml and then acidified with acid formic. The 
purified cytokinins were dried in SpeedVac, dissolved into 100 µl 5 % methanol in water and centrifuged. 
The obtained samples were then analyzed in LC-MS and compared. The experiments were tested in 
triplicate. 
 
To confirm that BpLOG is able to produces 6-O-Methylguanine, we directly applied a 
MS/MS approach to the isolated physiological product and to 6-O-Methylguanine 
standard in order to compare the two fragmentation mass spectra. We used collision 
energy of 25 a.u for both and observed that the two recorded fragmentation mass 
profiles corresponded with each other. This comparison gave the definitive proof that 
BpLOG synthetizes the 6-O-Methylguanine as physiological product (Fig. 20), in 








Figure 20. LC-MS/MS analysis of 6-O-Methylguanine. The MS/MS study on the physiological product 
and on 6-O-methylguanine confirmed the identity of the product synthetized by BpLOG. The collision 
energy used for the fragmentation was of 25 a.u.  
 
Noteworthy is that we obtained the same results also for bacterial lysates and that the 
product 6-O-Methylguanine was found in clinical isolate strains supernatant B3629 and 








4.6  BpLOG IS PREVALENTLY EXPRESSED IN CLINICAL 
ISOLATES 
 
To verify the expression of BpLOG in B. pertussis, we performed a Western 
Immunoblot analysis on total extracts and on supernatants of different strains. These 
strains were the lab strain Tohama I and two epidemic strains, B3621 and B3629, 
isolated in France in 2008 and in 2009 with the characteristic of not expressing the 
vaccine component pertactin and to have a novel allele for the promoter ptxP3 that lets 
B. pertussis to produce more pertussis toxin (Bart, van der Heide et al. 2015). The 
Δ1253 was used as negative control and the purified protein as positive control. The 
strains were grown for 24 hours and then lysed, whilst the proteins secreted in 
supernatants were TCA precipitated. The WB analysis evidenced that BpLOG is 
expressed in total extracts of bacteria and that is more expressed in clinical isolates 












Figure 21. BpLOG is prevalently expressed in clinical isolates. In Western Immunoblot was compared 
the expression of BpLOG between Tohama I, clinical isolates B3629 and B3621, and Δ1253 strains. 
Bacterial lysates and supernatants were analyzed. The pellet of 1 OD of each strain was dissolved in 100 
µl of loading buffer with reducing agent and heated at 70°C. From these, 30 µl were loaded onto the gel. 
The corresponding supernatants, after TCA precipitation, were dissolved in 20 µl of loading buffer with 
reducing agent, heat inactivated and loaded onto the gel. It resulted out that BpLOG is present in total 
extracts and that is prevalently expressed in epidemic strains. The experiment was performed with mouse 
polyclonal α-BP1253 (1:500). 25 ng purified protein was the positive control. The panel on the left 
stained Red Ponceau was presented as control of equal loading of the proteins. Different experiments 
gave identical results. 
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4.7  BpLOG IS NEGATIVELY RELATED TO OXIDATIVE 
STRESS 
 
In Mycobacterium tuberculosis has been recently described that an excess of cytokinins 
breakdown products could represent a source of toxicity for the bacterium, especially an 
accumulation of p-topolin degradation product pHBA that in the presence of Nitric 
Oxide (NO) could induce death of the mycobacterium itself. For this reason the MtLOG 
half-life is highly regulated by the proteasome that controls the level of MtLOG 
(Naseem, Sarukhanyan et al. 2015, Samanovic and Darwin 2015, Samanovic, Tu et al. 
2015, Zhu and Javid 2015). Since BpLOG is a homologous of MtLOG and since we 
know that it produces 6-O-Methylguanine, we tested in the same oxidative stress 
conditions the Tohama I strain and Δ1253 to estimate if even the presence of 6-O-
Methylguanine can induce differences of survival between the two strains and make the 
wild type more sensitive. After a 24-hour growth we incubated the cultures for 30 
minutes with 100 mM and 300 mM of hydrogen peroxide (H2O2) and following the 
treatment the bacteria were plated and their viability was measured (Fig. 22). From this 
oxidative stress condition emerged that Δ1253 strain showed a greater resistance to 
hydrogen peroxide than the wild type. Indeed, Tohama I bacteria treated with 100 mM 
of hydrogen peroxide presented a percentage of viability of 58.8 % instead knockout 
strain exhibited a survival rate of 73.11 %. The same trend was observed also for the 
samples exposed at 300 mM of hydrogen peroxide. In these extreme conditions the wild 
type and Δ1253 showed a viability of 18.34 % and 35.84 % respectively. In both 
treatments was measured a difference in the survival capability at oxidative stress 

























Figure 22. Tohama I and Δ1253 treated with H2O2. The Δ1253 strain presented a greater resistance to 
hydrogen peroxide. The Tohama I and Δ1253 strains after a 24 hours growth in Steiner-Scholte medium 
were treated for 30 minutes with 100mM and 300 mM of H2O2. Before treatment the corresponding OD 
was measured. At the end of the treatment a dilution of 109 bacteria were plated on Bordet-Gengou agar 
plates and incubated at 37°C for three days. Finally, the number of colonies was counted. All samples 
exposed to H2O2 were compared to not treated samples with Kruskal-Wallis test. Samples incubated with 
300 mM were statistically significantly with p value of 0.02. The others were not statistically significantly 
but we recorded a continuous decrease in vitality with increasing H2O2 concentration. The values 
presented represent the means ± SD of three independent experiments. 
 
To verify that this recorded toxicity is due to the presence of 6-O-Methylguanine with 
H2O2, we incubated the two strains of interest either with 6-O-Methylguanine 10 µM 
alone or in combination with 100 mM H2O2 (Fig. 23). In the first case we observed a 
survival rate comparable to the not treated bacteria in both strains, on the contrary, in 
bacteria treated with H2O2 and 6-O-Methylguanine together, we noticed a considerable 
reduction of viability. In the wild type the survival percentage dropped to 19.8 %, in 
Δ1253 to 34.9 %. These percentages resulted much lower than that obtained incubating 
the bacteria only with H2O2 (Fig. 24). From this control experiment we confirmed that 
6-O-Methylguanine alone is not toxic for B. pertussis, but in combination with 














Figure 23. Tohama I and Δ1253 treated with 6-O-Methylguanine and H2O2.  6-O-Methylguanine in 
presence of hydrogen peroxide results to be toxic. The bacteria were grown for 24 hours, after that the 
OD was measured and a group of strains were incubated for 30 minutes with 6-O-Methylguanine 10 µM 
and another group with H2O2 100 mM and 6-O-Methylguanine 10 µM. After treatment a dilution of 109 
bacteria were plated on BG agar plates and incubated at 37°C for three days for colony counts. The 
percentage of samples exposed to only 6-O-Methylguanine were based on not treated bacteria, the ratio of 
the groups treated either with 6-O-Methylguanine that with H2O2 was calculated on the base of colony 
number of groups treated only with 6-O-Methylguanine. The values presented represent the means ± SD 












Figure 24. Effects of 6-O-Methylguanine with H2O2. Viability comparison between non treated 
bacteria, samples exposed to 100 mM of hydrogen peroxide and samples treated with 6-O-Methylguanine 
10 µM and H2O2 100 mM. In Tohama I strain 10 µM of 6-O-Methylguanine reduces the viability of 
bacteria treated only with H2O2 of 37%, in Δ253 strains the adding of 10 µM of 6-O-Methylguanine at 
















Nowadays increasingly cases of Whooping cough infections are reported in all age 
groups with the consequent increase in mortality among infants. This resurgence of 
pertussis infection is seriously concerning the public health. As described previously, 
causes may be correlated to aP vaccines that induce a short last immunity not able to 
prevent colonization and transmission. In addition, the lack of herd immunity and the 
vaccine selection that leading to diffusion of Bordetella strains could exert a key role. 
Therefore, is necessary to increase our knowledge on B. pertussis microbiology in order 
to improve or find new strategies to existing ones. In this study we focused our attention 
on a protein of B. pertussis with unknown function so far. This protein named BP1253 
and referred by us as BpLOG, was previously classified as lysine decarboxylase since it 
contains a PGGxGTxxE motif present also in the LOG family. LOG proteins have a 
phosphoribohydrolase activity, which consists in the cleavage of the N-glycosidic 
linkage between modified bases in position 6, prevalently adenines, and the ribose 5’-
monophosphate moiety. Through this activity, LOG proteins synthetize and release 
cytokinins, phytohormones implicated in the control of many aspects of plants growth, 
defense and development. In silico analyses and in vitro experiments have demonstrated 
that BpLOG is a member of the LOG family. It shares the PGGxGTxxE motif and the 
catalytic amino acids Arg and Glu, it is able to bind AMP with a kd of 5.7 µM and 
exerts phosphoribohydrolase activity towards AMP. Of interest was to discover that 
BpLOG can also bind other nucleotides like GMP, IMP and dinucleotides such as NAD, 
NADH and NADP. In addition, we found that surprisingly BpLOG has a higher 
phosphoribohydrolase activity towards GMP and CMP than AMP, though the 
dissociation constant for CMP was not detectable. This apparent discrepancy could be 
due to a strong instability of the substrate protein complex that results in a rapid release 
of the reaction products and in undetectable kd. A lower stability of the GMP-BpLOG 
complex compared to the AMP-BpLOG complex could also be the reason why GMP 
shows a higher kd than AMP. Currently, LOGs proteins are divided in two clusters 
based on their oligomeric state and each cluster is in turn further classified in two 
groups based on the amino acids present in the binding site. In silico analyses have 
shown that BpLOG has a primary structure similar to hexameric type-II LOGs. Based 
on the sequence homology, BpLOG would result a type-II LOG, but our studies have 
shown that the oligomeric state of BpLOG is dimeric. Moreover, the amino acid 
residues of the binding site are not represented in any subgroup. This latter, could 
explain the capability of this protein to bind and hydrolyze more effectively alternative 
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substrates like GMP and CMP. In the light of these differences we hypothesize that 
BpLOG could represent a further sub-group of type-II LOG or be the first characterized 
LOG of a new interposed group between the type-I and type-II LOG. 
The peculiarities that distinguish BpLOG and make it unique are found also in the 
production of the physiological cytokinins. Generally, the cytokinins are adenine-
derivatives modified at N6, but BpLOG produces the 6-O-Methylguanine, a guanine-
derivative with a methyl-group at O6. Though the compounds known to possesses 
cytokinin activity are adenine derivatives, synthesized O6-substituted guanine and 
hypoxanthine derivatives, have been described to act as cytokinins and induce cell 
division in plants (Hashizume, Sakai et al. 1976). Although the synthesis of the 6-O-
Methylguanine as cytokinin could surprise, it sounds perfectly in agreement with the 
higher phosphoribohydrolase activity of BpLOG against GMP. Since BpLOG is able to 
produce a cytokinin-like compound different from the classical cytokinins and has 
substrate flexibility towards other nucleotides, we suppose that BpLOG is likely able to 
synthetize also other non-canonical cytokinins based on guanine and even on cytosine, 
compounds not identified with the methodology used in this study. 
The presence of classical cytokinins was investigated and the isopentenyl-adenine and 
the kinetin were found in the bacterial lysates of B. pertussis both in wild type Tohama I 
and in Δ1253 (data not shown) revealing no differences between the two strains. The 
production of modified adenine cytokinins is likely due to the presence of BP0547 
classified as lysine decarboxylase, but which shares with LOGs the PGGxGTxxE motif 
and the catalytic amino acids. Sequence alignments with LOGs revealed that BP0547 is 
more similar to type-I LOG and has an identity of 54% with the characterized type-I P. 
aeruginosa LOG (Seo and Kim 2018) and greater homology than BpLOG with MtLOG, 
described to synthetize adenine-derivate cytokinins (Samanovic, Tu et al. 2015). In 
addition, PSORT-B prediction for BP0547 resulted in a cytoplasmic localization, while 
the TMHMM 2.0 server predicted for BP1253 a possible transmembrane helix at amino 
acids 36-58. Accordingly BpLOG could be most likely located in periplasmic space or 
on the external membrane. The different cellular localization of the two proteins could 
explain the presence of isopentenyl-adenine and kinetin in bacterial lysates, while 6-O-
Methylguanine is released in the extracellular space. We have not found adenine-
derivate cytokinins in the supernatant of wild type Bp, which could be explained by the 
low amount secreted, though we cannot exclude that BpLOG could be involved in the 
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biochemical pathway of canonical cytokinins. However, BpLOG is certainly the 
responsible of the synthesis of 6-O-Methylguanine. 
The capability of BpLOG to recognize and metabolize several substrates could be 
further explained if we consider this protein as an enzyme equipped with a dual 
function. In Saccharomyces cerevisiae the overexpression of the analogous LOG1 
(YJL055W) gene conferred resistance to nucleotide analogues chemotherapeutic drugs. 
The LOG protein encoded by this gene is able to detoxify the purine analogue 6-N-
hydroxylaminopurine (HAP) and the pyrimidine analogue 5-fluorouracil (5-FU) 
(Carlsson, Hu et al. 2018). Based on the detoxification properties of this LOG, we may 
hypothesize that BpLOG, besides producing and releasing 6-O-Methylguanine in the 
extracellular milieu, could also protect B. pertussis by degrading non-canonical 
nucleotides that could come from external environment and interfere with the normal 
development of the bacterium. 
In plant, cytokinins are hormones that act locally or distant from the cell at very low 
concentrations (Dolezal, Popa et al. 2007). They modulate plant metabolism and 
morphogenesis in response to environmental factors such as light, water and nutrients 
(Hirose, Takei et al. 2008). At high concentrations, instead, cytokinins induce the plants 
to mount defenses against the attack of pathogens (Naseem, Wolfling et al. 2014). In 
plants, hence, the cytokinins are molecules involved in cellular communication 
triggering transcriptional changes to adapt the organism to environmental stress. Likely, 
under environmental stimuli, the 6-O-Methylguanine is released from B. pertussis as 
means of inter-bacteria communication to trigger the expression of specific genes and 
let the bacterium to adapt to these stimuli. Recently, the existence of a cytokinin 
signaling has been demonstrated in M. tuberculosis (Samanovic, Hsu et al. 2018). 
Through this signaling, isopentenyl-adenine, one of the most abundant cytokinin in M. 
tuberculosis, is able to regulate the expression of some genes like the Rv0077c and 
Rv0078. The first one encodes for an oxidoreductase, while the second one for its TetR-
like regulator. The regulation of Rv0077c resulted in a loss of acid-fast staining of M. 
tuberculosis, generally associated with changes in bacterial envelope and virulence 
(Samanovic, Hsu et al. 2018). The cytokinin receptor in mammalian-pathogen has not 
been identified yet, but it is interesting to note that the cytokinin receptors in plants, 
fungi and phytopathogenic bacteria are structurally and functionally very similar to 
bacterial receptors associated to virulence, like the two-component regulatory system 
BvgAS (Steklov, Lomin et al. 2013, Wang, Cheng et al. 2017, Kabbara, Schmulling et 
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al. 2018). In plants the several classes of cytokinins are sensed via a two-component 
signaling phosphorelays, but the cyclase/histidine kinases-associated sensing 
extracellular (CHASE) domain, that binds cytokinins and triggers the signaling cascade, 
has not homologues proteins in Bordetella species. 
Some studies have demonstrated that different cytokinins promote cellular 
differentiation or apoptosis in immune cells (Casati, Ottria et al. 2011), affect the 
production of cytokines (Ciaglia, Pisanti et al. 2014) and reduce inflammatory response 
(Lappas 2015, Santoro, Ciaglia et al. 2018). This latter suggested us that B. pertussis 
may secrete along with toxins also cytokinins, including 6-O-Methylguanine, to reshape 
the host immune system to its advantage though further investigation is necessary to 
confirm that 6-O-Methylguanine is released to modulate immune system synergistically 
with virulence factors. 
In this thesis we have reported that the cytokinin-like 6-O-Methylguanine is negatively 
related to oxidative stress. Indeed, in the absence of 6-O-Methylguanine, the knockout 
Δ1253 strain treated with different concentrations of hydrogen peroxide, resulted more 
resistant than wild type Tohama I strain in the same conditions. After the addition of 6-
O-Methylguanine to the growth medium during the treatment, Δ1253 strain reached 
survival rates comparable to those of wild type. Therefore, the 6-O-Methylguanine or its 
breakdown products could react with H2O2 producing a compound toxic for the 
bacterium. Similar results were recently obtained in M. tuberculosis (Samanovic, Tu et 
al. 2015), the non-proteasome regulation of MtLOG made the human-pathogen 
sensitive to nitric oxide (NO). Indeed, the overexpression of MtLOG led to an 
accumulation of cytokinin degradation products that interacting with NO produced toxic 
aldehydes. These results led us to speculate that adenine or guanine derivate molecules 
can react with reactive nitrogen and oxygen species (NOS, ROS) for their physical and 
chemical properties in oxidative stress conditions. It is interesting to note that to 
promote the bacterial clearance one of innate immune response during Bordetella 
infection is precisely the release of NOS and ROS in airways, as in the case of the 
Stimulated Innate Resistance (StIR) based on ROS production (Zurita, Moreno et al. 
2013). Therefore, the host could exploit the interaction of ROS with 6-O-Methylguanine 
to promote the clearance of B. pertussis. However, since we found a greater expression 
of BpLOG in the clinical isolates strains compared to laboratory strain, we think that 
this protein is involved in infection. Our experiments on the effects of 6-O-
Methylguanine in combination with H2O2 were all carried out in vitro and we do not 
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know what could happen in vivo. In alternative the release of 6-O-Methylguanine could 
be toxic for epithelial cells helping the colonization of B. pertussis. In agreement with 
this hypothesis, kinetin, which possesses antioxidant proprieties, was found in the Bp 
lysates (Brizzolari, Marinello et al. 2016, Othman, Naseem et al. 2016, Ahanger, 
Alyemeni et al. 2018, Honig, Plihalova et al. 2018). B. pertussis may produce the 
cytokinin kinetin to protect itself against oxidative stress while the release of 6-O-
Methylguanine in combination with ROS can favor bacteria colonization. 
All these features make BpLOG a novel exciting protein virtually involved in a whole 
unknown pathway in the mammalian-pathogen microbiology. This could open new 
branches in the research of B. pertussis treatments. Indeed, the importance of BpLOG in 
the medical field is increased if we consider that BpLOG homologous proteins are 
absent in humans. Accordingly, BpLOG could become a new pharmaceutical target in 
novel therapeutic strategies and represent an interesting research object in the study of 






This work was sponsored by Novartis Vaccines; in March 2015 the Novartis non-
influenza Vaccines business was acquired by the GSK group of companies. The sponsor 
was involved in all stages of the study conduct and analysis. 
Conflict of Interest statement: Filippo Moramarco participated in a post graduate 
studentship program at GSK. 
















1. Ahanger, M. A., M. N. Alyemeni, L. Wijaya, S. A. Alamri, P. Alam, M. Ashraf 
and P. Ahmad (2018). "Potential of exogenously sourced kinetin in protecting 
Solanum lycopersicum from NaCl-induced oxidative stress through up-
regulation of the antioxidant system, ascorbate-glutathione cycle and glyoxalase 
system." PLoS One 13(9): e0202175. 
2. Bajguz, A. and A. Piotrowska (2009). "Conjugates of auxin and cytokinin." 
Phytochemistry 70(8): 957-969. 
3. Bari, R. and J. D. Jones (2009). "Role of plant hormones in plant defence 
responses." Plant Mol Biol 69(4): 473-488. 
4. Bart, M. J., H. G. van der Heide, A. Zeddeman, K. Heuvelman, M. van Gent and 
F. R. Mooi (2015). "Complete Genome Sequences of 11 Bordetella pertussis 
Strains Representing the Pandemic ptxP3 Lineage." Genome Announc 3(6). 
5. Bart, M. J., A. Zeddeman, H. G. van der Heide, K. Heuvelman, M. van Gent and 
F. R. Mooi (2014). "Complete Genome Sequences of Bordetella pertussis 
Isolates B1917 and B1920, Representing Two Predominant Global Lineages." 
Genome Announc 2(6). 
6. Baugh, L., I. Phan, D. W. Begley, M. C. Clifton, B. Armour, D. M. Dranow, B. 
M. Taylor, M. M. Muruthi, J. Abendroth, J. W. Fairman, D. Fox, 3rd, S. H. 
Dieterich, B. L. Staker, A. S. Gardberg, R. Choi, S. N. Hewitt, A. J. Napuli, J. 
Myers, L. K. Barrett, Y. Zhang, M. Ferrell, E. Mundt, K. Thompkins, N. Tran, 
S. Lyons-Abbott, A. Abramov, A. Sekar, D. Serbzhinskiy, D. Lorimer, G. W. 
Buchko, R. Stacy, L. J. Stewart, T. E. Edwards, W. C. Van Voorhis and P. J. 
Myler (2015). "Increasing the structural coverage of tuberculosis drug targets." 
Tuberculosis (Edinb) 95(2): 142-148. 
7. Boucher, P. E., A. E. Maris, M. S. Yang and S. Stibitz (2003). "The response 
regulator BvgA and RNA polymerase alpha subunit C-terminal domain bind 
simultaneously to different faces of the same segment of promoter DNA." Mol 
Cell 11(1): 163-173. 
8. Boucher, P. E., K. Murakami, A. Ishihama and S. Stibitz (1997). "Nature of 
DNA binding and RNA polymerase interaction of the Bordetella pertussis BvgA 
transcriptional activator at the fha promoter." J Bacteriol 179(5): 1755-1763. 
9. Brizzolari, A., C. Marinello, M. Carini, E. Santaniello and P. A. Biondi (2016). 
"Evaluation of the antioxidant activity and capacity of some natural N6-
substituted adenine derivatives (cytokinins) by fluorimetric and 
61 
 
spectrophotometric assays." J Chromatogr B Analyt Technol Biomed Life Sci 
1019: 164-168. 
10. Carbonetti, N. H. (2010). "Pertussis toxin and adenylate cyclase toxin: key 
virulence factors of Bordetella pertussis and cell biology tools." Future 
Microbiol 5(3): 455-469. 
11. Carlsson, M., G. Z. Hu and H. Ronne (2018). "Gene dosage effects in yeast 
support broader roles for the LOG1, HAM1 and DUT1 genes in detoxification 
of nucleotide analogues." PLoS One 13(5): e0196840. 
12. Casati, S., R. Ottria, E. Baldoli, E. Lopez, J. A. Maier and P. Ciuffreda (2011). 
"Effects of cytokinins, cytokinin ribosides and their analogs on the viability of 
normal and neoplastic human cells." Anticancer Res 31(10): 3401-3406. 
13. Christie, C. D. and R. S. Baltimore (1989). "Pertussis in neonates." Am J Dis 
Child 143(10): 1199-1202. 
14. Ciaglia, E., S. Pisanti, P. Picardi, C. Laezza, S. Sosa, A. Tubaro, M. Vitale, P. 
Gazzerro, A. M. Malfitano and M. Bifulco (2014). "N6-isopentenyladenosine 
affects cytotoxic activity and cytokines production by IL-2 activated NK cells 
and exerts topical anti-inflammatory activity in mice." Pharmacol Res 89: 1-10. 
15. Confer, D. L. and J. W. Eaton (1982). "Phagocyte impotence caused by an 
invasive bacterial adenylate cyclase." Science 217(4563): 948-950. 
16. Cookson, B. T., A. N. Tyler and W. E. Goldman (1989). "Primary structure of 
the peptidoglycan-derived tracheal cytotoxin of Bordetella pertussis." 
Biochemistry 28(4): 1744-1749. 
17. Cortleven, A. and T. Schmulling (2015). "Regulation of chloroplast 
development and function by cytokinin." J Exp Bot 66(16): 4999-5013. 
18. Cotter, P. A. and J. F. Miller (1994). "BvgAS-mediated signal transduction: 
analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a 
rabbit model." Infect Immun 62(8): 3381-3390. 
19. Cowell, J. L., E. L. Hewlett and C. R. Manclark (1979). "Intracellular 
localization of the dermonecrotic toxin of Bordetella pertussis." Infect Immun 
25(3): 896-901. 
20. Cummings, C. A., H. J. Bootsma, D. A. Relman and J. F. Miller (2006). 
"Species- and strain-specific control of a complex, flexible regulon by 
Bordetella BvgAS." J Bacteriol 188(5): 1775-1785. 
62 
 
21. de Gouw, D., D. A. Diavatopoulos, H. J. Bootsma, P. W. Hermans and F. R. 
Mooi (2011). "Pertussis: a matter of immune modulation." FEMS Microbiol Rev 
35(3): 441-474. 
22. Decker, K. B., T. D. James, S. Stibitz and D. M. Hinton (2012). "The Bordetella 
pertussis model of exquisite gene control by the global transcription factor 
BvgA." Microbiology 158(Pt 7): 1665-1676. 
23. Dobrev, P. I., K. Hoyerova and J. Petrasek (2017). "Analytical Determination of 
Auxins and Cytokinins." Methods Mol Biol 1569: 31-39. 
24. Dolezal, K., I. Popa, E. Hauserova, L. Spichal, K. Chakrabarty, O. Novak, V. 
Krystof, J. Voller, J. Holub and M. Strnad (2007). "Preparation, biological 
activity and endogenous occurrence of N6-benzyladenosines." Bioorg Med 
Chem 15(11): 3737-3747. 
25. Dzurova, L., F. Forneris, S. Savino, P. Galuszka, J. Vrabka and I. Frebort 
(2015). "The three-dimensional structure of "Lonely Guy" from Claviceps 
purpurea provides insights into the phosphoribohydrolase function of Rossmann 
fold-containing lysine decarboxylase-like proteins." Proteins 83(8): 1539-1546. 
26. Edwards, J. A., N. A. Groathouse and S. Boitano (2005). "Bordetella 
bronchiseptica adherence to cilia is mediated by multiple adhesin factors and 
blocked by surfactant protein A." Infect Immun 73(6): 3618-3626. 
27. El-Azami-El-Idrissi, M., C. Bauche, J. Loucka, R. Osicka, P. Sebo, D. Ladant 
and C. Leclerc (2003). "Interaction of Bordetella pertussis adenylate cyclase 
with CD11b/CD18: Role of toxin acylation and identification of the main 
integrin interaction domain." J Biol Chem 278(40): 38514-38521. 
28. el Baya, A., K. Bruckener and M. A. Schmidt (1999). "Nonrestricted differential 
intoxication of cells by pertussis toxin." Infect Immun 67(1): 433-435. 
29. Elliott, E., P. McIntyre, G. Ridley, A. Morris, J. Massie, J. McEniery and G. 
Knight (2004). "National study of infants hospitalized with pertussis in the 
acellular vaccine era." Pediatr Infect Dis J 23(3): 246-252. 
30. Gan, S. and R. M. Amasino (1995). "Inhibition of leaf senescence by 
autoregulated production of cytokinin." Science 270(5244): 1986-1988. 
31. Giron, D., E. Frago, G. Glevarec, C. M. J. Pieterse and M. Dicke (2013). 
"Cytokinins as key regulators in plant–microbe–insect interactions: connecting 
plant growth and defence." Functional Ecology 27(3): 599-609. 
63 
 
32. Glaser, P., A. Danchin, D. Ladant, O. Barzu and A. Ullmann (1988). "Bordetella 
pertussis adenylate cyclase: the gene and the protein." Tokai J Exp Clin Med 13 
Suppl: 239-252. 
33. Glaser, P., A. Elmaoglou-Lazaridou, E. Krin, D. Ladant, O. Barzu and A. 
Danchin (1989). "Identification of residues essential for catalysis and binding of 
calmodulin in Bordetella pertussis adenylate cyclase by site-directed 
mutagenesis." Embo j 8(3): 967-972. 
34. Graf, R., J. Codina and L. Birnbaumer (1992). "Peptide inhibitors of ADP-
ribosylation by pertussis toxin are substrates with affinities comparable to those 
of the trimeric GTP-binding proteins." Mol Pharmacol 42(5): 760-764. 
35. Guermonprez, P., N. Khelef, E. Blouin, P. Rieu, P. Ricciardi-Castagnoli, N. 
Guiso, D. Ladant and C. Leclerc (2001). "The adenylate cyclase toxin of 
Bordetella pertussis binds to target cells via the alpha(M)beta(2) integrin 
(CD11b/CD18)." J Exp Med 193(9): 1035-1044. 
36. Guevara, C., C. Zhang, J. A. Gaddy, J. Iqbal, J. Guerra, D. P. Greenberg, M. D. 
Decker, N. Carbonetti, T. D. Starner, P. B. McCray, Jr., F. R. Mooi and O. G. 
Gomez-Duarte (2016). "Highly differentiated human airway epithelial cells: a 
model to study host cell-parasite interactions in pertussis." Infect Dis (Lond) 
48(3): 177-188. 
37. Hashizume, T., S. Sakai, T. Sugiyama and S. Matsubara (1976). "Cytokinin 
activity of O6-substituted guanine and hypoxanthine derivatives." 
Phytochemistry 15(12): 1813-1815. 
38. Heiss, L. N., S. A. Moser, E. R. Unanue and W. E. Goldman (1993). 
"Interleukin-1 is linked to the respiratory epithelial cytopathology of pertussis." 
Infect Immun 61(8): 3123-3128. 
39. Henderson, I. R., F. Navarro-Garcia, M. Desvaux, R. C. Fernandez and D. 
Ala'Aldeen (2004). "Type V protein secretion pathway: the autotransporter 
story." Microbiol Mol Biol Rev 68(4): 692-744. 
40. Higgs, R., S. C. Higgins, P. J. Ross and K. H. Mills (2012). "Immunity to the 
respiratory pathogen Bordetella pertussis." Mucosal Immunol 5(5): 485-500. 
41. Hinsch, J., J. Vrabka, B. Oeser, O. Novak, P. Galuszka and P. Tudzynski (2015). 
"De novo biosynthesis of cytokinins in the biotrophic fungus Claviceps 
purpurea." Environ Microbiol 17(8): 2935-2951. 
64 
 
42. Hirose, N., K. Takei, T. Kuroha, T. Kamada-Nobusada, H. Hayashi and H. 
Sakakibara (2008). "Regulation of cytokinin biosynthesis, compartmentalization 
and translocation." J Exp Bot 59(1): 75-83. 
43. Honig, M., L. Plihalova, L. Spichal, J. Gruz, A. Kadlecova, J. Voller, A. R. 
Svobodova, J. Vostalova, J. Ulrichova, K. Dolezal and M. Strnad (2018). "New 
cytokinin derivatives possess UVA and UVB photoprotective effect on human 
skin cells and prevent oxidative stress." Eur J Med Chem 150: 946-957. 
44. Inatsuka, C. S., S. M. Julio and P. A. Cotter (2005). "Bordetella filamentous 
hemagglutinin plays a critical role in immunomodulation, suggesting a 
mechanism for host specificity." Proc Natl Acad Sci U S A 102(51): 18578-
18583. 
45. Inatsuka, C. S., Q. Xu, I. Vujkovic-Cvijin, S. Wong, S. Stibitz, J. F. Miller and 
P. A. Cotter (2010). "Pertactin is required for Bordetella species to resist 
neutrophil-mediated clearance." Infect Immun 78(7): 2901-2909. 
46. Jeon, W. B., S. T. Allard, C. A. Bingman, E. Bitto, B. W. Han, G. E. Wesenberg 
and G. N. Phillips, Jr. (2006). "X-ray crystal structures of the conserved 
hypothetical proteins from Arabidopsis thaliana gene loci At5g11950 and 
AT2g37210." Proteins 65(4): 1051-1054. 
47. Kabbara, S., T. Schmulling and N. Papon (2018). "CHASEing Cytokinin 
Receptors in Plants, Bacteria, Fungi, and Beyond." Trends Plant Sci 23(3): 179-
181. 
48. Kamanova, J., O. Kofronova, J. Masin, H. Genth, J. Vojtova, I. Linhartova, O. 
Benada, I. Just and P. Sebo (2008). "Adenylate cyclase toxin subverts phagocyte 
function by RhoA inhibition and unproductive ruffling." J Immunol 181(8): 
5587-5597. 
49. Kotob, S. I., S. Z. Hausman and D. L. Burns (1995). "Localization of the 
promoter for the ptl genes of Bordetella pertussis, which encode proteins 
essential for secretion of pertussis toxin." Infect Immun 63(8): 3227-3230. 
50. Kowalzik, F., A. P. Barbosa, V. R. Fernandes, P. R. Carvalho, M. L. Avila-
Aguero, D. Y. Goh, A. Goh, J. G. de Miguel, F. Moraga, J. Roca, M. Campins, 
M. Huang, J. Quian, N. Riley, D. Beck and T. Verstraeten (2007). "Prospective 
multinational study of pertussis infection in hospitalized infants and their 
household contacts." Pediatr Infect Dis J 26(3): 238-242. 
65 
 
51. Kuchar, E., M. Karlikowska-Skwarnik, S. Han and A. Nitsch-Osuch (2016). 
"Pertussis: History of the Disease and Current Prevention Failure." Adv Exp 
Med Biol 934: 77-82. 
52. Kukimoto-Niino, M., K. Murayama, M. Kato-Murayama, M. Idaka, Y. Bessho, 
A. Tatsuguchi, R. Ushikoshi-Nakayama, T. Terada, S. Kuramitsu, M. Shirouzu 
and S. Yokoyama (2004). "Crystal structures of possible lysine decarboxylases 
from Thermus thermophilus HB8." Protein Sci 13(11): 3038-3042. 
53. Kurakawa, T., N. Ueda, M. Maekawa, K. Kobayashi, M. Kojima, Y. Nagato, H. 
Sakakibara and J. Kyozuka (2007). "Direct control of shoot meristem activity by 
a cytokinin-activating enzyme." Nature 445(7128): 652-655. 
54. Ladant, D., S. Michelson, R. Sarfati, A. M. Gilles, R. Predeleanu and O. Barzu 
(1989). "Characterization of the calmodulin-binding and of the catalytic domains 
of Bordetella pertussis adenylate cyclase." J Biol Chem 264(7): 4015-4020. 
55. Lappas, C. M. (2015). "The plant hormone zeatin riboside inhibits T lymphocyte 
activity via adenosine A2A receptor activation." Cell Mol Immunol 12(1): 107-
112. 
56. Locht, C., L. Coutte and N. Mielcarek (2011). "The ins and outs of pertussis 
toxin." Febs j 278(23): 4668-4682. 
57. Lynfield, R. and W. Schaffner (2014). "Can we conquer coqueluche?" J Infect 
Dis 209 Suppl 1: S1-3. 
58. Mallory, F. B. and A. A. Hornor (1912). "Pertussis: The histological Lesion in 
the Respiratory Tract." J Med Res 27(2): 115-124.113. 
59. Mattoo, S. and J. D. Cherry (2005). "Molecular pathogenesis, epidemiology, and 
clinical manifestations of respiratory infections due to Bordetella pertussis and 
other Bordetella subspecies." Clin Microbiol Rev 18(2): 326-382. 
60. Mazar, J. and P. A. Cotter (2006). "Topology and maturation of filamentous 
haemagglutinin suggest a new model for two-partner secretion." Mol Microbiol 
62(3): 641-654. 
61. Mazar, J. and P. A. Cotter (2007). "New insight into the molecular mechanisms 
of two-partner secretion." Trends Microbiol 15(11): 508-515. 
62. McGregor, J., J. W. Ogle and G. Curry-Kane (1986). "Perinatal pertussis." 
Obstet Gynecol 68(4): 582-586. 
66 
 
63. Melvin, J. A., E. V. Scheller, J. F. Miller and P. A. Cotter (2014). "Bordetella 
pertussis pathogenesis: current and future challenges." Nat Rev Microbiol 12(4): 
274-288. 
64. Mooi, F. R., N. A. Van Der Maas and H. E. De Melker (2014). "Pertussis 
resurgence: waning immunity and pathogen adaptation - two sides of the same 
coin." Epidemiol Infect 142(4): 685-694. 
65. Naseem, M., E. Bencurova and T. Dandekar (2018). "The Cytokinin-Activating 
LOG-Family Proteins Are Not Lysine Decarboxylases." Trends Biochem Sci 
43(4): 232-236. 
66. Naseem, M., E. Sarukhanyan and T. Dandekar (2015). "LONELY-GUY Knocks 
Every Door: Crosskingdom Microbial Pathogenesis." Trends Plant Sci 20(12): 
781-783. 
67. Naseem, M., M. Wolfling and T. Dandekar (2014). "Cytokinins for immunity 
beyond growth, galls and green islands." Trends Plant Sci 19(8): 481-484. 
68. Nicholson, T. L. (2007). "Construction and validation of a first-generation 
Bordetella bronchiseptica long-oligonucleotide microarray by transcriptional 
profiling the Bvg regulon." BMC Genomics 8: 220. 
69. Nieves, D. J. and U. Heininger (2016). "Bordetella pertussis." Microbiol Spectr 
4(3). 
70. Othman, E. M., M. Naseem, E. Awad, T. Dandekar and H. Stopper (2016). "The 
Plant Hormone Cytokinin Confers Protection against Oxidative Stress in 
Mammalian Cells." PLoS One 11(12): e0168386. 
71. Paddock, C. D., G. N. Sanden, J. D. Cherry, A. A. Gal, C. Langston, K. M. Tatti, 
K. H. Wu, C. S. Goldsmith, P. W. Greer, J. L. Montague, M. T. Eliason, R. C. 
Holman, J. Guarner, W. J. Shieh and S. R. Zaki (2008). "Pathology and 
pathogenesis of fatal Bordetella pertussis infection in infants." Clin Infect Dis 
47(3): 328-338. 
72. Porter, J. F., R. Parton and A. C. Wardlaw (1991). "Growth and survival of 
Bordetella bronchiseptica in natural waters and in buffered saline without added 
nutrients." Appl Environ Microbiol 57(4): 1202-1206. 
73. Radhika, V., N. Ueda, Y. Tsuboi, M. Kojima, J. Kikuchi, T. Kudo and H. 
Sakakibara (2015). "Methylated Cytokinins from the Phytopathogen 




74. Ramakrishnan, L., N. A. Federspiel and S. Falkow (2000). "Granuloma-specific 
expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS 
family." Science 288(5470): 1436-1439. 
75. Sakamoto, H., J. Bellalou, P. Sebo and D. Ladant (1992). "Bordetella pertussis 
adenylate cyclase toxin. Structural and functional independence of the catalytic 
and hemolytic activities." J Biol Chem 267(19): 13598-13602. 
76. Samanovic, M. I. and K. H. Darwin (2015). "Cytokinins beyond plants: 
synthesis by Mycobacterium tuberculosis." Microb Cell 2(5): 168-170. 
77. Samanovic, M. I., H. C. Hsu, M. B. Jones, V. Jones, M. R. McNeil, S. H. 
Becker, A. T. Jordan, M. Strnad, C. Xu, M. Jackson, H. Li and K. H. Darwin 
(2018). "Cytokinin Signaling in Mycobacterium tuberculosis." MBio 9(3). 
78. Samanovic, M. I., S. Tu, O. Novak, L. M. Iyer, F. E. McAllister, L. Aravind, S. 
P. Gygi, S. R. Hubbard, M. Strnad and K. H. Darwin (2015). "Proteasomal 
control of cytokinin synthesis protects Mycobacterium tuberculosis against nitric 
oxide." Mol Cell 57(6): 984-994. 
79. Santoro, A., E. Ciaglia, V. Nicolin, A. Pescatore, L. Prota, M. Capunzo, M. V. 
Ursini, S. L. Nori and M. Bifulco (2018). "The isoprenoid end product N6-
isopentenyladenosine reduces inflammatory response through the inhibition of 
the NFkappaB and STAT3 pathways in cystic fibrosis cells." Inflamm Res 
67(4): 315-326. 
80. Schmidt, G., U. M. Goehring, J. Schirmer, M. Lerm and K. Aktories (1999). 
"Identification of the C-terminal part of Bordetella dermonecrotic toxin as a 
transglutaminase for rho GTPases." J Biol Chem 274(45): 31875-31881. 
81. Seo, H. and K. J. Kim (2017). "Structural basis for a novel type of cytokinin-
activating protein." Sci Rep 7: 45985. 
82. Seo, H. and K. J. Kim (2018). "Structural and biochemical characterization of 
the type-II LOG protein from Streptomyces coelicolor A3." Biochem Biophys 
Res Commun 499(3): 577-583. 
83. Seo, H. and K. J. Kim (2018). "Structural insight into molecular mechanism of 
cytokinin activating protein from Pseudomonas aeruginosa PAO1." Environ 
Microbiol. 
84. Seo, H., S. Kim, H. Y. Sagong, H. F. Son, K. S. Jin, I. K. Kim and K. J. Kim 
(2016). "Structural basis for cytokinin production by LOG from 
Corynebacterium glutamicum." Sci Rep 6: 31390. 
68 
 
85. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, M. D. 
Provenzano, E. K. Fujimoto, N. M. Goeke, B. J. Olson and D. C. Klenk (1985). 
"Measurement of protein using bicinchoninic acid." Anal Biochem 150(1): 76-
85. 
86. Stein, P. E., A. Boodhoo, G. D. Armstrong, S. A. Cockle, M. H. Klein and R. J. 
Read (1994). "The crystal structure of pertussis toxin." Structure 2(1): 45-57. 
87. Steklov, M. Y., S. N. Lomin, D. I. Osolodkin and G. A. Romanov (2013). 
"Structural basis for cytokinin receptor signaling: an evolutionary approach." 
Plant Cell Rep 32(6): 781-793. 
88. Trainor, E. A., T. L. Nicholson and T. J. Merkel (2015). "Bordetella pertussis 
transmission." Pathog Dis 73(8): ftv068. 
89. Tuomanen, E. I. and J. O. Hendley (1983). "Adherence of Bordetella pertussis to 
human respiratory epithelial cells." J Infect Dis 148(1): 125-130. 
90. Uhl, M. A. and J. F. Miller (1994). "Autophosphorylation and phosphotransfer 
in the Bordetella pertussis BvgAS signal transduction cascade." Proc Natl Acad 
Sci U S A 91(3): 1163-1167. 
91. Vandebriel, R. J., S. M. Hellwig, J. P. Vermeulen, J. H. Hoekman, J. A. 
Dormans, P. J. Roholl and F. R. Mooi (2003). "Association of Bordetella 
pertussis with host immune cells in the mouse lung." Microb Pathog 35(1): 19-
29. 
92. Villarino Romero, R., R. Osicka and P. Sebo (2014). "Filamentous 
hemagglutinin of Bordetella pertussis: a key adhesin with immunomodulatory 
properties?" Future Microbiol 9(12): 1339-1360. 
93. Wang, F. F., S. T. Cheng, Y. Wu, B. Z. Ren and W. Qian (2017). "A Bacterial 
Receptor PcrK Senses the Plant Hormone Cytokinin to Promote Adaptation to 
Oxidative Stress." Cell Rep 21(10): 2940-2951. 
94. Warfel, J. M., J. Beren, V. K. Kelly, G. Lee and T. J. Merkel (2012). 
"Nonhuman primate model of pertussis." Infect Immun 80(4): 1530-1536. 
95. Warfel, J. M., L. I. Zimmerman and T. J. Merkel (2014). "Acellular pertussis 
vaccines protect against disease but fail to prevent infection and transmission in 
a nonhuman primate model." Proc Natl Acad Sci U S A 111(2): 787-792. 
96. Weiss, A. A. and S. Falkow (1983). "Transposon insertion and subsequent donor 




97. Weiss, A. A., E. L. Hewlett, G. A. Myers and S. Falkow (1983). "Tn5-induced 
mutations affecting virulence factors of Bordetella pertussis." Infect Immun 
42(1): 33-41. 
98. Werner, T., V. Motyka, M. Strnad and T. Schmulling (2001). "Regulation of 
plant growth by cytokinin." Proc Natl Acad Sci U S A 98(18): 10487-10492. 
99. World Health Organization (2015). "Pertussis vaccines: WHO position paper - 
September 2015." Wkly Epidemiol Rec 90(35): 433-458. 
100. Zhu, J. H. and B. Javid (2015). "Tuberculosis: hey there, lonely guy!" 
Mol Cell 57(6): 951-952. 
101. Zlamy, M. (2016). "Rediscovering Pertussis." Front Pediatr 4: 52. 
102. Zurita, E., G. Moreno, A. Errea, M. Ormazabal, M. Rumbo and D. 
Hozbor (2013). "The stimulated innate resistance event in Bordetella pertussis 
infection is dependent on reactive oxygen species production." Infect Immun 
81(7): 2371-2378. 
 
